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THE EMERGING ROLE OF ASTROCYTES IN THE PATHOPHYSIOLOGY OF 
SCHIZOPHRENIA 
 
1.1 Schizophrenia is a severe psychiatric disorder 
Schizophrenia is a chronic, debilitating psychiatric illness afflicting over three 
million people in the United States and 1% of the population worldwide and is associated 
with a high incidence of drug abuse, depression, homelessness, and suicide (Tamminga 
and Holcomb, 2005).  There is no test or biological marker that unambiguously identifies 
this illness, which manifests with a heterogeneous pattern of symptoms that can obscure 
personality and intellect and rob individuals of their ability to pursue an independent life.   
The symptoms of schizophrenia, which affect thought, perception, affect, and 
behavior, fall into three broad categories: positive, negative, and cognitive symptoms.  
Positive symptoms are usually rapid in onset and are characterized by the existence of 
behaviors not normally present, such as hallucinations, delusions, and disorders of 
thought, speech, and movement.  Conversely, negative symptoms are characterized by 
the absence of normal mood and behaviors, including flattening of affect, poverty of 
speech, diminished pleasure and volition, social withdrawal, and, in extreme cases, 
catatonia.  Cognitive symptoms, the third broad category, are a central feature of this 
disease and are characterized by deficits in attention, working memory, and executive 
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functioning.  While there is no cure for schizophrenia, there are pharmacological and 
nonpharmacological methods of treatment.  The drugs currently available are only 
moderately effective for relieving many of these symptoms and, unfortunately, 
medication-induced side effects often make treatment a potentially undesirable 
alternative to living with the untreated illness.  On average, symptoms of schizophrenia 
emerge beginning in adolescence to about 30 years of age, though males tend to present 
at a younger age than females.   
 
1.2 A developmental hypothesis of schizophrenia 
It is hypothesized that schizophrenia is the result of genetic and environmental 
factors.  Monozygotic twins have a 40-65% concordance rate and about 10% of people 
with schizophrenia in first degree relatives will go on to develop the illness.  Several 
genes associated with developmental functions including neuronal migration, 
synaptogenesis, neuronal and glial differentiation, neurotransmission, synaptic plasticity, 
and receptor trafficking and anchoring have been identified as increasing susceptibility to 
schizophrenia (Harrison and Weinberger, 2005).  Clearly, a genetic predisposition is not 
solely culpable.  When paired with in utero complications (especially during the second 
trimester) such as maternal exposure to viruses, or perinatal complications such as fetal 
hypoxia, or even those that occur early in life following birth, neurodevelopment may be 
disrupted and thus set the stage for later emergence of the illness (Cannon et al., 2003; 
Rapoport et al., 2005).  However, neither one specific genetic profile nor a critical 
threshold for environmental insult is known.  Even with these purported factors in place, 
there is a period of relative quiescence from birth to late adolescence when symptoms are 
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absent or significantly muted.  As adolescence gives way to adulthood, biological events 
such as neurological restructuring may perturb developmental abnormalities and unmask 
previously dormant vulnerabilities (Cotter and Pariante, 2002).  Psychosocial stressors 
and environmental factors such as urban vs. rural upbringing and substance abuse are also 
correlated with the emergence of schizophrenia (Hambrecht and Hafner, 1996; Henquet 
et al., 2005; Allardyce and Boydell, 2006; Kristensen and Cadenhead, 2007). 
Despite the fact that overt symptoms are initially not present, there is evidence 
that disease-related abnormalities are in place before diagnosable symptoms of 
schizophrenia materialize.  For example, early in childhood the offspring of affected 
individuals have been shown to demonstrate schizophrenia-like symptoms and structural 
brain anomalies prior to illness manifestation (Cannon et al., 2003; Rajarethinam et al., 
2004).  Additionally, the unaffected siblings of individuals with schizophrenia often show 
hallmark characteristics of the illness such as structural brain changes, decreased 
performance on cognitive tasks, and behavioral symptoms that resemble schizophrenia 
(Kendler and Diehl, 1993; Cannon et al., 2000), although it is not understood why certain 
individuals with these phenotypic characteristics do not become ill.   
The advent of brain imaging tools has allowed researchers to identify underlying 
brain pathology in schizophrenia, which include enlarged ventricles, an overall decrease 
in cerebral gray and white matter volume, loss of cortical and hippocampal volume, and 
altered metabolic activity in the brain (Cotter and Pariante, 2002; Tamminga and 
Holcomb, 2005).  Many of these changes are detectable at the first onset of 
schizophrenia.  Work with postmortem brain tissue has revealed that the macroscopic 
neuropathology identified by in vivo imaging is associated with cytoarchitectural 
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abnormalities, including changes in cellular size, morphology, location, and orientation 
(Harrison, 1999).  Until recently, a majority of these abnormalities were thought to be 
static, and thus, a neuroprogressive model of illness development was not strongly 
embraced.  There are now reports, however, which suggest that the initial onset of 
schizophrenia may be characterized by rapid and progressive degeneration that eventually 
tapers off to form a more stable set of illness characteristics (Ho et al., 2003; Pantelis et 
al., 2005; Rapoport et al., 2005).  One longitudinal neuroimaging study showed that 
adolescent patients with schizophrenia had a significant and rapid loss of gray matter 
compared to typical age-related losses in a non-psychiatrically ill comparison group 
(Thompson et al., 2001).  These losses progressed across a span of several cortical 
regions in a temporal manner.  The parietal and motor cortices showed rapid loss of gray 
matter that appeared in early adolescence, whereas frontal and temporal regions did not 
exhibit deficits until late adolescence after the appearance of symptoms (Cannon et al., 
2000).    
A conventional sign of an active degenerative state in the brain is “reactive 
gliosis” of a specialized type of glial cell—the astrocyte, which includes hypertrophy of 
astrocytic processes and upregulation of intermediate filament proteins.  This has been 
reported in progressive neurodegenerative disorders such as Parkinson’s, Huntington’s, 
and Alzheimer’s diseases, and amyotrophic lateral sclerosis (Maragakis and Rothstein, 
2006; Wilhelmsson et al., 2006).  Gliosis is a sensitive indicator of neurodegeneration 
and injury in the brain and was hypothesized to exist in schizophrenia.  Although 
reported in early studies of schizophrenia (Stevens, 1982), these findings have not been 
replicated, and instead may have been due to brain abnormalities secondary to the illness 
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(Roberts et al., 1986; Roberts et al., 1987; Stevens et al., 1988; Casanova et al., 1990; 
Falkai et al., 1999; Damadzic et al., 2001).   
 
1.3 Neurotransmitter system abnormalities in schizophrenia  
Alterations in several neurotransmitter systems have been identified in 
schizophrenia.  A model of dopamine hyperfunction arose amid findings that 
dopaminergic agonists, such as the psychostimulant amphetamine, were found to induce 
a schizophrenia-like psychosis in some nonpsychiatrically ill individuals and exacerbate 
existing symptoms in individuals with schizophrenia (Guillin et al., 2007).  Additional 
pharmacological support for this model arose when antipsychotic medications that act by 
blocking D2-like dopamine receptors were shown to successfully reduce some symptoms 
of schizophrenia (Laruelle et al., 2003).  Today, there are ample data that reflect 
dysfunction in the dopaminergic system in schizophrenia (Carlsson et al., 2001).  One 
major caveat to the dopamine hypothesis of schizophrenia, however, is that D2 receptor 
antagonists only effectively treat positive symptoms and have far more modest effects on 
cognitive and negative symptoms.  Other dopamine receptor subtypes have since been 
identified and implicated in this illness, and consequently, a refined theoretical model has 
been developed to link the idea of both hyper- and hypo-function of the dopamine 
system, which better accounts for cognitive and negative symptoms (Davis et al., 1991; 
Guillin et al., 2007).   
Although other transmitter systems have emerged as potential contributors to this 
illness, including, but not limited to, serotonin, gamma-aminobutyric acid (GABA), and 
acetylcholine, dysfunctional glutamatergic transmission, in particular, has emerged as a 
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predominant hypothesis for the pathophysiology of schizophrenia (Roth et al., 2003; 
Wassef, 2003; Sarter et al., 2005; Coyle, 2006; Abi-Dargham and Guillin, 2007; Guillin 
et al., 2007).  An extensive amount of research has produced data to support the idea of 
glutamate dysfunction in schizophrenia, including findings of altered expression of 
numerous molecules involved in glutamate synthesis, transport, binding, reuptake, and 
recycling (Ohnuma et al., 1998; Ibrahim et al., 2000; Ohnuma et al., 2000; Meador-
Woodruff et al., 2001; Smith et al., 2001b; Smith et al., 2001a; Gluck et al., 2002; 
McCullumsmith and Meador-Woodruff, 2002; Burbaeva et al., 2003; Bruneau et al., 
2005 and Harrison et al., 2003 for review).  Furthermore, unlike the dopamine 
hypothesis, glutamatergic dysfunction accounts for the spectrum of symptoms seen in 
schizophrenia.  Some have suggested that dopamine dysfunction may in fact be 
secondary to glutamatergic abnormalities (Laruelle et al., 2003).   
In glutamatergic transmission, glutamine is supplied to neurons by transport from 
astrocytes.  Within neurons, glutamine is converted to glutamate and packaged into 
synaptic vesicles.  The release of this presynaptic glutamate from neurons activates 
receptors located on pre- and postsynaptic neurons, as well as those located 
perisynaptically on astrocytes.  These receptors include metabotropic glutamate receptors 
(mGluRs), which are G-protein coupled, and three types of ionotropic glutamatergic 
receptors: the N-methyl-D-aspartate (NMDA), α-amino-3-hydroxy-5-methylisoxazole-4-
propionic acid (AMPA), and kainate receptors (Figure 1.1).  The NMDA receptor is 
unique in several ways.  First, it is both a ligand and ion gated receptor, meaning that it 
requires binding of an agonist (in this case glutamate) as well as membrane 





Figure 1.1 The glutamate synapse.  The release of glutamate from neuronal presynaptic 
terminals activates receptors located on pre- and postsynaptic neurons and astrocytes.  
These receptors include mGluRs, which are G-protein coupled, and three types of 





activation.  Several agents act on the co-agonist binding site of the NMDA receptor, 
including glycine and D-serine (Matsui et al., 1995).  Upon receptor activation, calcium 
(Ca2+) flows into the cell and modulates gene expression through a cascade of signaling 
mechanisms.  Extended activation of NMDA, along with AMPA receptors, can cause 
morphological changes to postsynaptic dendritic spines and facilitate long term 
potentiation (LTP), a momentary or long term enhanced synaptic signaling that occurs in 
learning and memory (Mothet et al., 2006).  
A glutamate hypothesis of schizophrenia arose, like the dopamine hypothesis, 
from a pharmacological observation.  Phencyclidine (PCP), which had been used as an 
anesthetic, was shown to induce symptoms resembling the positive, negative and 
cognitive symptoms of schizophrenia in non-psychiatrically ill patients, and magnify 
those symptoms in patients with schizophrenia (Javitt, 1987).  PCP was shown to act as a 
noncompetitive antagonist of the NMDA receptor.  This finding, together with the fact 
that other NMDA receptor antagonists, including ketamine, also elicit a “schizophrenia-
like” syndrome, helped establish a model of NMDA receptor hypofunction in 
schizophrenia (Lahti et al., 1995; Coyle, 1996).  Many studies have since reported altered 
expression of the NMDA receptor, including receptor subunits and binding sites, as well 
as associated postsynaptic density proteins which facilitate intracellular signaling 
(Clinton et al., 2003; Laruelle et al., 2003; Meador-Woodruff et al., 2003; and for review 
see Kristiansen et al., 2007).  Furthermore, NMDA receptor hypofunction is supported by 
data demonstrating that co-agonists of the receptor, which facilitate receptor function, can 
attenuate some symptoms of schizophrenia (Heresco-Levy et al., 2005).   
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1.4 Structural and functional brain abnormalities in schizophrenia 
The positive, negative, and cognitive symptoms of schizophrenia are most 
certainly the result of impairment in multiple brain regions.  The prefrontal cortex (PFC) 
emerged early on as a major site of this dysfunction (Weinberger et al., 1986).  Normal 
functioning of this area depends on reciprocal connections with other structures 
including, but not limited to, the superior temporal gyrus, cingulate cortex, hippocampus, 
and primary visual cortex.  All of these corticolimbic structures have been implicated in 
the pathophysiology of schizophrenia by volumetric changes, abnormal activation, and 
aberrant functional connectivity (Assaf et al., 2006; Garrity et al., 2007).   
 
1.4.1 Prefrontal cortex.   
Perhaps the most prevalent subset of symptoms, as well as the most devastating 
and treatment-resistant, is cognitive impairment.  This often manifests as the inability to 
sustain attention, loss of executive functioning, and loss of the ability to initiate and 
execute goal-directed behaviors.   Working memory, the capacity to actively hold 
information in short term memory, is key to this type of cognition.  The PFC plays a 
critical role in high-level executive functioning.  Years of research have clearly shown 
that this area is compromised in schizophrenia (Weinberger and Berman, 1996; Manoach, 
2003).  Imaging studies demonstrate that working memory deficits are associated with 
reduced activation in the dorsolateral PFC during cognitive tasks (Weinberger et al., 
1986; Perlstein et al., 2001; Assaf et al., 2006).  While some postmortem studies 
demonstrate layer-specific reductions in neuronal size and density in the PFC (Rajkowska 
et al., 1998), others report increased neuronal density and reduced interneuronal space 
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between pyramidal and nonpyramidal neurons, suggesting an overall loss of neuropil 
(Selemon et al., 1995; Selemon and Goldman-Rakic, 1999).  The PFC is one of the last 
brain areas to reach maturation.  This maturation culminates with processes such as 
synaptic pruning of prefrontal cortical regions in late adolescence, a time that coincides 
with the emergence of symptoms of schizophrenia, adding further evidence to support the 
notion of prefrontal cortical dysfunction playing a role in this illness (Woo and Crowell, 
2005).   
 
1.4.2 Superior temporal gyrus.   
The superior temporal gyrus has been associated with abnormalities in speech, 
language processing, and the performance of working memory tasks.  This brain region is 
comprised of several specialized areas, including Wernicke’s area, which is vital for 
processing and understanding speech.  The superior temporal gyrus also contains the 
primary auditory cortex, which integrates auditory information into perception, and has 
also been implicated in the manifestation of auditory hallucinations (Stephane et al., 
2001).  In vivo imaging studies that have focused on the superior temporal gyrus show 
that this area does not exhibit typical levels of deactivation during working memory tasks 
in patients with schizophrenia compared to normal controls (Walter et al., 2007).  
Furthermore, treatment with antipsychotic drugs relieves symptoms, improves working 
memory, and returns activation patterns during working memory tasks to levels 
comparable to nonpsychiatrically ill individuals (Wolf et al., 2007).  Other in vivo 
imaging studies show a volumetric loss in the left anterior superior temporal gyrus in 
schizophrenia, a change that correlates with the presence of severe thought disorder 
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(Rajarethinam et al., 2000).  Consistent with loss of volume and aberrant connectivity, 
postmortem studies show evidence of synaptic abnormalities in this region that become 
more pronounced with age (Sokolov et al., 2000) 
 
1.4.3 Cingulate cortex.   
The cingulate cortex plays an important role in cognition, the ability to sustain 
attention and motivation, as well as emotion and affect.  Studies have uncovered multiple 
abnormalities of the cingulate in schizophrenia, including structural, functional, and gene 
expression changes in this region (Tamminga et al., 2000).  A meta-analysis of multiple 
in vivo imaging studies examining the cingulate cortex reported a volume reduction in 
schizophrenia (Baiano et al., 2007).  Other studies report that diminished performance on 
semantic memory tasks correlates with increased activation of the cingulate cortex (Assaf 
et al., 2006).   Postmortem evidence of pathology in the cingulate, which includes 
decreased neuronal density in this region, is consistent with volume decreases reported in 
in vivo imaging studies (Benes et al., 1986; Benes et al., 1991; Benes et al., 2001).  A 
large scale proteomics study found that 36 different proteins, including metabolic, 
cytoskeletal, synaptic, signaling, trafficking, and glial proteins, were abnormally 
expressed in the cingulate cortex in schizophrenia, suggesting wide-spread dysfunction 
(Clark et al., 2006).  
 
1.4.4 Hippocampus.   
The hippocampus plays a pivotal role in learning as well as verbal and spatial 
memory via its connections with virtually all association cortices.  Diminished cognitive 
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processing and evidence of structural and functional pathology have also implicated the 
hippocampus in schizophrenia (Heckers, 2001; Harrison, 2004).  In vivo imaging studies 
of the hippocampus show volumetric losses in schizophrenia, especially on the left side, 
even in first episode patients (Heckers, 2001; Steen et al., 2006).   Consistent with this 
evidence of hippocampal volume loss, postmortem studies have revealed evidence of 
cytoarchitectural abnormalities in the hippocampus of patients with schizophrenia, 
including decreased neuronal density and decreased expression of synaptic proteins such 
as NMDA and AMPA receptors (Eastwood and Harrison, 2000; Gothelf et al., 2000; 
Harrison et al., 2003; Coyle, 2004).  Additionally, positive symptoms involving auditory 
hallucinations have been attributed to hippocampal dysfunction (Boyer et al., 2007).  All 
of these data have been hypothesized to reflect abnormal circuitry between the 
hippocampal region and the PFC (Winterer et al., 2003; Meyer-Lindenberg et al., 2005).   
 
1.4.5 Primary visual cortex.   
The primary visual cortex has not always been thought to be involved in the 
pathophysiology of schizophrenia, and in fact, has been used as a “control” cortical 
region which is compared to other areas in some studies.  Evidence is emerging, 
however, that may suggest otherwise (Dracheva et al., 2001; Dracheva et al., 2005).  The 
primary visual cortex is involved in both form recognition and object location, the latter 
of which involves saccadic eye movements, a mechanism governed by the frontal cortex 
and a common deficit in schizophrenia (Tamminga and Holcomb, 2005).  In vivo imaging 
studies have revealed decreased regional activation in the primary visual cortex of 
patients with schizophrenia who have received minimal antipsychotic treatment, as well 
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as in those who have had long term treatment (Desco et al., 2003).  Several postmortem 
studies show that cortical volume, neuronal density, and neuropil volume are altered in 
the visual cortex in schizophrenia, although there is disagreement regarding the direction 
of changes (Selemon et al., 1995; Selemon and Goldman-Rakic, 1999; Dorph-Petersen et 
al., 2007).   
This is by no means a complete picture of the pathology present or the multiple 
regions affected in this illness; rather it is a simplified snapshot of broad cortical and 
limbic dysfunction inherent in schizophrenia.  The pathological aspects of schizophrenia, 
including evidence of degeneration (despite a lack of gliosis), macroscopic structural and 
functional abnormalities, neurotransmitter-related dysfunction, and cell level pathology, 
can all be traced back to disruption during neurodevelopment.  
 
1.5 Nervous system development 
Neurodevelopment consists of distinct segments, all of which are highly 
conserved phylogenetically.  From neurogenesis, the initial birth of cells, through 
differentiation into specific cell types, migration to destined regions, synapse formation, 
and survival beyond pruning, multiple signaling molecules, both secreted and local, 
induce, guide, and organize cells into a structurally and functionally complex units (Sun 
et al., 2002).  Early in the development of the nervous system, cells from the ectoderm 
layer begin to acquire neuronal characteristics.  These progenitor cells located in the 
ventricular zone, an area of extensive neurogenesis, will differentiate to give rise to 
various types of neural tissue.  This differentiation process produces two major cell 
lineages in the brain, neurons and glia, and is driven by a series of inducing factors, such 
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as sonic hedgehog and glial growth factor, from neighboring cells (Gotz and Huttner, 
2005).  Differentiation is followed by a period of mass cellular migration that coincides 
with the second trimester of pregnancy in humans.  During this time, cells leave the 
ventricular zone and form the cortical plate, which eventually gives rise to cortical gray 
matter.   
Radial glial cells play several critical roles during these early developmental 
stages of neurogenesis, differentiation, and migration (Ever and Gaiano, 2005).  Most, if 
not all, neuronal cell types can arise from radial glia (Malatesta et al., 2000; Anthony et 
al., 2004; Gotz and Huttner, 2005).  These glial progenitor cells reside in the ventricular 
zone and extend processes that terminate at the upper pial surface, thus providing a 
physical guide to which newly differentiated cells may cling as they migrate from the 
ventricular zone to their destined location in the developing brain.  With the radial glia 
assisting, these differentiated cells arrange in a predictable manner to form cortical layers 
via an “inside out” pattern.  Radial glial cells also provide metabolic support for 
neighboring cells and release signaling factors to guide axonal and dendritic 
differentiation (Song et al., 2002).  Concurrent with neurogenesis, but not before, radial 
glia can themselves differentiate into many types of glial cells. 
 During the final phase of early neurodevelopment, newly migrated cells 
differentiate to express a specific neurotransmitter phenotype.  Intracellular factors, as 
well as environmental signals from cells targeted for synaptic connection, help determine 
this fate.  Whether synaptic connections or the cells themselves survive, and a majority 
do not, depends on a class of trophic factors from the target cells, such as neurotrophic 
growth factor (NGF), brain derived neural growth factor (BDNF), and transforming 
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growth factor (TGFβ) (Alvarez-Buylla and Garcia-Verdugo, 2002).  These neurotrophins 
incite a cascade of intracellular signaling which results in either cell death or survival.  In 
this manner, cells organize into functional tissue with sensing and signaling capabilities. 
 
1.5.1 Developmental gene abnormalities in schizophrenia.   
Schizophrenia is a complex illness that involves the dysfunction of multiple 
components, all of which are consistent with a developmental origin.  A heritable 
predisposition for abnormal gene function that disrupts cellular migration and/or alters 
the mechanisms of growth factors could establish a prenatal vulnerability to this illness.  
This vulnerability, when paired with pre- or postnatal epigenetic factors, can result in 
structural brain abnormalities that lead to schizophrenia. 
Several genes regulating developmental processes described above have been 
implicated in schizophrenia (Harrison and Weinberger, 2005).  For example, neuregulin 1 
(NRG1), which plays a role in cellular differentiation in association with glial growth 
factor, has been linked to genetic susceptibility for schizophrenia.  Recent reports indicate 
that abnormal cellular migration during development, which is thought to account for 
many of the cytoarchitectural abnormalities seen in schizophrenia, may be attributed to 
NRG1 dysfunction, and that catechol-O-methyl transferase (COMT), another molecule 
thought to impart susceptibility to schizophrenia, may compound this dysfunction (Jakob 
and Beckmann, 1985; Sei et al., 2007).  Additional evidence derives from animal studies, 
which show that modifying NRG1 gene expression can perturb early neurodevelopment 
and produce animals that exhibit abnormal behavior analogous to that induced by PCP, a 
drug that, as noted earlier, causes a spectrum of schizophrenia-like symptoms in humans 
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(Falls, 2003).  Consistent with these data, human postmortem studies have shown 
increased NRG1 mRNA in the dorsolateral prefrontal cortex (DLPFC) and hippocampus 
in schizophrenia (Harrison and Law, 2006).   
In addition to abnormal differentiation and migration, studies suggest that 
alterations in genes that affect synapse formation and neuronal survival, such as BDNF, 
may contribute to the development of structural abnormalities seen in schizophrenia 
(Weickert et al., 2003; Sugai et al., 2005).  What is particularly notable is that these 
structural changes, even when localized, can have a global impact.  Studies find that 
prenatal hippocampal lesions in the rat result in predominant abnormalities in the cortex 
(Bertolino et al., 2002; Lipska, 2004).  These structural abnormalities coincide with 
marked behavioral changes and sensitivity to NMDA receptor antagonists such as PCP, 
suggesting a relationship between structural abnormalities, behavior, and glutamatergic 
dysfunction.  Likewise, structural abnormalities in patients with schizophrenia, such as 
enlarged ventricles and loss of cortical gray and white matter, correlate with symptom 
severity (Ho et al., 2003; Bearden et al., 2007).   
Together, this body of research shows that when neurodevelopmental processes 
are disturbed, even at the level of individual genes or signaling factors, they can produce 
significant structural, functional and behavioral abnormalities.  Schizophrenia research 
abounds with evidence of such abnormalities, which have until recently been largely 
attributed to neurons.  However, a novel component of brain dysfunction in schizophrenia 




1.6 The role of glial cells in brain function 
The name glia has had several meanings attributed to it, some rather unflattering 
(e.g. slime) though the most likely is that of “glue”, which is based on the perceived 
function of these cells as structural cohesive elements within the brain.  This task of 
providing support to neurons, the “functional units” of the brain, was thought to be the 
raison d'etre of glia.  Thus, not much interest was shown in them beyond their initial 
characterization.  Research efforts have since uncovered diverse and important functions 
for these cells which far exceed their role as mere scaffolding.   
Brain matter is composed of cells that derive from two major cell lineages: 
neuronal cells, which are comprised of a number of morphologically and functionally 
distinct members, and glial cells, which may be further defined as either macro- or 
microglia.  Glial cells outnumber neurons in the mammalian central nervous system 
(CNS) by about ten to one (Coyle and Schwarcz, 2000).  Compared to other primates, 
humans have an even higher glia to neuron ratio in the frontal cortex, the area of the brain 
most associated with higher cognition.  It seems likely that through evolution the 
successful emergence of more complex neural connections was paralleled by a system 
that could accommodate increased metabolic demands and facilitate more rapid 
transmission (Sherwood et al., 2006).  Vertebrates are thought to have developed cells 
specialized to meet those demands, a role fulfilled today by macroglial cell types, 
including astrocytes and oligodendrocytes.   
 
1.6.1 Biology and function of oligodendrocytes.   
Oligodendrocytes are found exclusively in the CNS, where they produce a lipid-
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rich myelin sheath to extend and wrap in layers around neuronal axons.  The myelination 
process promotes neuronal development and survival and facilitates rapid and accurate 
transmission of nerve impulses (Griffiths et al., 1998).  The propagation of nerve 
impulses is further mediated by oligodendritic influence on the formation and 
maintenance of sodium channels at the nodes of Ranvier (Dupree et al., 2005).  
Reciprocal communication between oligodendrocytes and neurons during brain 
development is crucial.  Later, in the mature CNS, communication between 
oligodendrocytes, neurons, and astrocytes ensures that the integrity of the myelin sheath, 
and, therefore, neuronal signaling, is preserved (Itoh et al., 1995; Barres and Raff, 1999; 
Ishibashi et al., 2006).    
 
1.6.2 Identity of astrocytes.   
During the later stages of cortical development that follow neurogenesis, radial 
glial cells lose their stem cell qualities except in specific locations such as the 
subventricular zone (SVZ) and the subgranular layer of the dentate gyrus in the 
hippocampus (Alvarez-Buylla and Garcia-Verdugo, 2002) and differentiate into macro- 
and microglia (Figure 1.2).  Within the CNS, macroglia further differentiate into several 
different types of cells, including astrocytes that can be further classified as protoplasmic 
astrocytes of the gray matter and the more ramified fibrous astrocytes of the white matter.  
Oligodendrocytes are also located in CNS white matter and are responsible for 
myelination there.  Other CNS macroglia include the radial shaped Bergmann glia of the 
cerebellum and Müller cells of the retina (Alvarez-Buylla et al., 2002).  Recently, a novel 





Figure 1.2 Cell lineage. Neurons and glia arise from progenitor cells and differentiate 
into specific cell types.  Within the CNS, astrocytes may differential into either macro- or 
microglial cells.  Microglial cells are small mobile cells that phagocytize debris in the 
CNS, act as immune cells, and mount an inflammatory response to brain trauma.  
Macroglia further differentiate into: astrocytes, oligodendrocytes, synantocytes, and 





named for the Greek “to contact” because of their characteristic interactions in synapses 
and at nodes of Ranvier, comprise a group of cells that morphologically resemble the 
protoplasmic variety of astrocytes (Butt et al., 2002).  However, synantocytes can be 
identified by their thin, pale processes, irregular shaped nuclei, thinner mitochondria, and 
a greater number of ribosomes associated with the endoplasmic reticulum (Peters, 2004).  
Some of these cell types are relatively easy to discriminate from one another because of 
distinctive localization, morphology, and function.  Within the cerebrum, however, 
defining what is and is not an astrocyte is the subject of some debate (Walz, 2000). 
Astrocytic cells exhibit a high degree of heterogeneity, which has created 
controversy as to whether astrocytes should be thought of as one cell type that displays 
multiple characteristics or if there are actually several subtypes, each with distinguishing 
physiological and morphological features that persist throughout development to 
eventually give rise to distinct astrocyte populations in the mature brain.  Often, several 
of these characteristics must be used to differentially identify this diverse cell type (Walz, 
2000; Kimelberg, 2004).   
Since there is evidence which demonstrates that multiple astrocyte subtypes 
exhibit unique K+ currents, one method of distinguishing astrocyte subtypes is to 
compare the electrophysiological characteristics of the cells (Steinhauser et al., 1994).  
Astrocytes can be categorized as either “complex” or “passive” depending upon whether 
they demonstrated a voltage-dependent outward or an inward rectifying K+ current, 
respectively.  Using this classification, a pattern of traits supports the existence of at least 
two subtypes of astrocytes in the mouse hippocampus.  These two groups appear to differ 
in morphology, glutamate uptake currents and the expression of molecules that bind or 
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transport glutamate (Matthias et al., 2003).   
Further research by Zhou et al. has revealed that astrocytes exhibit distinct 
developmental phases where they display different electrophysiological phenotypes 
(Zhou et al., 2006).  Within the developing rat Cornu Ammonis (CA) 1 region of the 
hippocampus, three astrocytic phenotypes were described: astrocytes that are (a) outward 
rectifying (ORA), (b) variably rectifying (VRA), and (c) passive rectifying (PA).  These 
phenotypes appear in development in a linear manner beginning with the ORA type that 
is present and predominates at birth.  The VRA phenotype is also present at the time of 
birth, but to a lesser degree; it shows peak expression around postnatal day (pnd) 5, and 
then gradually tapers off to very low levels in the adult rat.  The ORA phenotype also 
declines with age, but unlike VRA astrocytes, it disappears around pnd 21.  The third 
astrocyte subgroup, the PA, appears at low levels around pnd 4, doubles its expression 
levels at pnd 14, and doubles again around pnd 21, making it the predominant astrocyte 
phenotype in the adult rat CA1 region.  The developmental progression of these three cell 
types include periods of overlap, especially during pnd 21, which suggests that this is a 
dynamic period of astrocyte differentiation in the rat CA1.  This idea is further supported 
by a parallel progression of the expression of certain cell surface molecules within these 
phenotypes (Zhou et al., 2006).  
Another method of differentiating astrocytes is via the labeling of molecular 
markers.  The cytoskeleton and process morphology of immature astrocytes are primarily 
made up of the intermediate filaments (IFs) vimentin and nestin (Eliasson et al., 1999).  
As astrocytes mature, vimentin and nestin are gradually replaced by another intermediate 
filament, glial fibrillary acidic protein (GFAP).  Co-expression of these filament proteins 
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is common within a period of developmental overlap, but in the mature astrocyte, co-
expression only occurs in astrocytes engaged in reactive gliosis (Eliasson et al., 1999).  
Accordingly, it is not uncommon for the identification of mature astrocytes in the CNS to 
be made by the presence GFAP (Eng et al., 1971).  Using this technique, several subtypes 
of astrocytes have been described, including the fibrous astrocytes and a protoplasmic 
variety (Walz, 2000).  Fibrous astrocytes, which have long, polarized processes, are 
mainly attributed to white matter areas, although these processes may extend into gray 
matter as well.   Protoplasmic astrocytes have short, ramified processes and are localized 
to gray matter areas in the brain.  Although both of these cells types have been shown to 
express GFAP, they do not always label as GFAP(+).  Several explanations for this 
phenomenon have been put forth.  One hypothesis is that GFAP expression may be so 
low within a subset of cells that it is virtually undetectable (Walz, 2000).  Support for this 
argument comes from models of brain trauma and injury.  Trauma-induced brain injury 
that leads to reactive gliosis is characterized by an increase in GFAP immunoreactivity 
without increasing cell proliferation, suggesting that existing cells that did not previously 
appear to express GFAP may, under these circumstances, do so (Walz, 2000; 
Wilhelmsson et al., 2006).  Another explanation for GFAP(-) astrocyte-like cells is that 
immunohistological detection methods may only recognize GFAP that is incorporated 
into the astrocyte cytoskeleton and fail to stain the soluble subunits, thereby providing a 
false negative for the presence of GFAP (Stichel et al., 1991).  
Using GFAP alone as an astrocytic marker can be problematic for several reasons, 
in part because not all astrocyte-like cells express GFAP and also because GFAP 
expression can change during development and under pathological conditions 
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(Steinhauser et al., 1994; Walz, 2000).  Another difficulty with using immunohistological 
labeling of GFAP to identify astrocytes is that GFAP is predominantly located in 
astrocyte processes, which prevents visualization of the entire cell.  Consequently, 
astrocytes have been mistakenly described as radial, star shaped cells (hence the name), 
which has inhibited the ability to study and understand the complete astrocyte landscape.  
Other immunohistochemical means of astrocyte identification can also be challenging.  
For instance, some studies have used the calcium binding protein S100β, which is 
expressed in mature astrocytes (Raponi et al., 2007).  However, S100β only labels the 
cell body, and, therefore, is not optimal for identifying complete cellular morphology 
either.  Furthermore, S100β is not expressed in astrocytes of the germinal zones, so it, 
too, only labels a subset of astrocytes (Raponi et al., 2007).  Other studies have identified 
astrocytes using GLAST, a glutamate transporter, however, this method carries the same 
limitations as S100β labeling (Kimelberg, 2004; Nishiyama et al., 2005).   Considering 
the diverse characteristics of astrocytes, it seems that, currently, the most accurate means 
of distinguishing them may be a combination of immunohistochemical labeling for 
several markers, including GFAP, S100β, GLAST and/or NG2 (in the case of 
synantocytes), along with morphological identification using a technique such as dye 
filling of astrocytes, which permits the entire cell to be visualized (Benediktsson et al., 
2005).     
Bushong et al. used the combined methods of immunolabeling for GFAP and 
S100β and dye-injecting individual astrocytes in the developing CA1 region of the rat 
hippocampus to demonstrate that astrocytes undergo several morphological changes 
throughout neurodevelopment (Bushong et al., 2004).  Tracking the progress of 
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astrocytes across a broad developmental span revealed distinct age-related morphologies 
that corresponded to patterns of physiological changes that had been previously 
described.  At pnd 7, a network of heterogeneous astrocytes with long, stringy, simplistic 
processes and some filopodial-like end feet were present.  By pnd 14, the cells were 
much more homogeneous in appearance, with evidence of individual domains beginning 
to develop.  Very fine astrocyte processes that were spongiform in nature became 
apparent by pnd 21, a time period when neighboring neuronal synapses also adopted a 
mature appearance.  Based on these morphological studies, the shape of many mature 
astrocytes is now known to be reminiscent of a rounded cube rather than entirely star 
shaped (Bushong et al., 2004).   
Astrocytes arrange themselves in space so that each cell occupies its own 
individual domain with boundaries that are defined by the spongiform processes.  Cells 
arrange with respect to these domain-forming processes with a characteristic regularity 
termed “contact spacing”, which was first described in the retina (Chan-Ling and Stone, 
1991).  It is notable that this contact spacing is not created by the more prominent GFAP-
containing processes of the astrocyte.  In fact, GFAP(+) processes are the minority in 
many brain regions, making up only about 15% of astrocyte mass in the rat hippocampus, 
for example (Bushong et al., 2002).  Although astrocytes may reach as many as 100,000 
synapses, there is very little overlap between the spongiform processes of adjacent 
astrocytes.   In fact, astrocytes only show minor overlap between larger processes and at 
the boundary interface where finer astrocytic processes connect with one another via gap 
junctions to form a syncytium (Distler et al., 1991).  This arrangement of astrocytes is 
consistent across brain regions and with other types of glia cells.  The Bergmann glia of 
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the cerebellum, for example, also occupy distinct microdomains of space (Grosche et al., 
1999).   
The distribution of astrocytes within a given brain area occurs in a region-specific 
manner.  Anatomical areas that are discernable by the distribution of neurons also show 
consistent patterns of astrocyte density within the same regional boundaries (Emsley and 
Macklis, 2006).  Additionally, the arrangement of astrocytes in some brain regions 
demonstrate functional borders, such as seen in the hippocampus which has at least two 
functionally distinct populations of  astrocytes (Zhou and Kimelberg, 2001; Zhou et al., 
2006).  Although the arrangement of astrocytes is regionally consistent and spatially 
distinct, morphology of individual cells may arise independent of region and be largely 
determined by the surrounding environment (Bushong et al., 2003).   
These data demonstrate that astrocytes exhibit distinct morphological and 
physiological features during development and that these developmental sequences 
proceed in tandem and culminate in predictable cellular shape and arrangement.  This 
suggests that astrocytes exhibit a set of characteristics that may be reliably determined.  
Furthermore, it describes a predictable arrangement of cells that is consistent with the 
various roles of astrocytes in maintaining brain function.   
 
1.6.3 Biology and function of astrocytes.   
Individual astrocytes can make contact with synapses numbering in the hundreds 
of thousands (Bushong et al., 2002).  Within gray matter, astrocytes physically extend 
processes into synapses, while in white matter they wrap their processes around many 
axons.  Additionally, astrocytes make physical contact with brain vasculature via endfoot 
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processes whereby they collect metabolic substrates and can induce vascular constriction 
via Ca2+-dependent second messenger systems (Mulligan and MacVicar, 2004).  
Astrocytes are also in chemical contact with non-neuronal cell types in the brain, such as 
oligodendrocytes, and influence their anatomical positions and functions.  In this way, 
astrocytes are able to monitor and respond in real time to an ever-changing environment 
by providing for the metabolic needs of neurons, regulating extracellular ion 
concentrations, influencing the number and stability of synaptic formations, synthesizing 
and recycling transmitter molecules, and facilitating cellular communication via the 
release of several transmitter molecules including Ca2+, glutamate, and D-serine (Allen 
and Barres, 2005; Escartin et al., 2006).   
Thus, neuronal functioning is irrevocably tied to astrocytes through numerous 
processes, and, as such, astrocytic dysfunction has the potential to directly and severely 
impact neuronal activity.   
 
1.6.4 Nutrient metabolism.   
Astrocytes monitor local brain activity and respond to activity-driven increases in 
cerebral blood flow by procuring glucose, the main source of energy in the brain, either 
from internal stores of glycogen or from nearby vasculature.  Astrocytes are anatomically 
positioned to form a continuum between neurons and the vascular system (Simard et al., 
2003; Zonta et al., 2003), making contact with the latter via end foot-bearing processes 
that express glucose transporter proteins (GLUT) 1 and 2 (Leloup et al., 1994; Leino et 
al., 1997) (Figure 1.3a).  Additionally, this positioning allows astrocytes to participate in 
the regulation of cerebral blood flow by inducing vascular dilation or constriction as 
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needed.  When astrocytes sense neuronal activity, glucose within the astrocyte undergoes 
glycolysis, a process that quickly produces lactic acid.  Astrocytes release lactic acid 
which may be taken up by neurons and subsequently converted to energy yielding 
adenosine triphosphate (ATP) molecules via the tricarboxylic acid cycle (Pellerin and 
Magistretti, 2004).  It has been hypothesized that another mode of delivering metabolic 
substrate is via the conversion of L-serine to pyruvate, a substance that can be used as a 
source of lactic acid.  This process is performed by serine racemase, an enzyme found 
predominantly in astrocytes (Foltyn et al., 2005).  In these ways, astrocytes rapidly 
provide neurons with replenishable energy sources.  Conversely, disturbing astrocyte 
metabolism leads to increased vulnerability of neurons to neurotoxic damage (Lian and 
Stringer, 2004). 
 
1.6.5 Ion metabolism.   
Astrocytes participate in the regulation of ion concentrations in the whole brain as 
well as in the synapse.  Bidirectional communication between astrocytes and neurons is 
accomplished by the release and uptake of ions such as Ca2+, K+, and H+.  K+ released 
during presynaptic depolarization is taken up by adjacent astrocytes and redistributed 
across an expanse of several astrocytes via gap junction coupling, a process called spatial 
buffering (Laming et al., 2000) (Figure 1.3b).  In this manner, the driving force of the K+ 
equilibrium potential moves K+ from an area of high concentration to an area of low 
concentration, away from the active neuron via astrocytes.  The intra- and extracellular 
pH of a given area fluctuates during processes such as neuronal activity and metabolism.  
Astrocytes regulate pH through several processes, including ion exchange and transport.  
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One way that astrocytes respond to changes in metabolic need is by altering the gene 
expression of molecules involved in metabolism (Magistretti, 2006).  Another method 
involves altering astrocyte morphology, as well as the morphology of surrounding 
neurons and synapses.   
 
1.6.6 Signaling.   
Another crucial way astrocytes monitor and respond to the environment is 
through the synthesis, release, and regulation of several signaling molecules such as (a) 
S100β, (b) Ca2+, (c) glutamate, and (d) D-serine. 
a. S100β.   
S100β, named for its solubility in 100% saturated ammonium sulfate solution, is a 
molecule expressed by astrocytes that participates in a multitude of Ca2+-dependent 
signaling cascades that influence the structure and function of both neurons and 
astrocytes (Rothermundt et al., 2003).  During development, S100β regulates cellular 
proliferation, differentiation, and synaptogenesis (Rothermundt et al., 2004a), then in the 
mature CNS, S100β accumulates in astrocytic processes where it modulates enzymatic 
activities, transcription factors, and protein phosphorylation (Zimmer et al., 1995).  
S100β expression also influences energy metabolism, calcium homeostasis, and cell 
growth and differentiation, including the degree of astrocytic process extension, in part, 
by regulating GFAP phosphorylation-dependent incorporation into the cytoskeleton 
(Garbuglia et al., 1999; Mbele et al., 2002) (Figure 1.3c).  S100β is secreted into the 
synapse by astrocytes where it is thought to play a role in synaptic plasticity (Nishiyama 
et al., 2005).   
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Inhibiting the expression of S100β in cultured astrocytes leads to altered 
morphology and proliferation of these cells (Selinfreund et al., 1990).  Additionally, 
changes in the expression of S100β can alter neuronal axon and dendrite growth 
(Whitaker-Azmitia et al., 1997; Nishiyama et al., 2002).  Conversely, in the absence of 
astrocytes, neuronal outgrowth in vivo and in vitro is severely limited, a phenomenon that 
may well depend upon S100β functionality (Nagler et al., 2001; Ullian et al., 2001; 
Ullian et al., 2004).  Alterations to the expression of S100β can also induce behavioral 
changes.  The over-expression of S100β in transgenic mice causes impaired spatial 
learning, decreased exploratory behavior, as well as a significant loss of neuronal 
branching (Gerlai et al., 1994; Whitaker-Azmitia et al., 1997; Winocura et al., 2001), 
whereas S100β-null mice, demonstrate enhanced synaptic plasticity, learning, and 
memory (Nishiyama et al., 2002).  The far reaching effects of S100β expression and 
signaling within astrocytes make clear the importance of this molecule in maintaining 
astrocyte-related brain function.  
b. Ca2+ signaling.   
Although glia were identified prior to neurons, the study of these cells was 
quickly cast aside in favor of the electrically excitable, and, therefore, presumably more 
important neuronal counterparts.  However, a renewed interest in astrocytes as active 
participants in brain signaling emerged in the early 1990s when it was shown that these 
cells were able to propagate Ca2+ waves (Cornell-Bell et al., 1990b; Charles et al., 1991).  
Astrocyte Ca2+ release in culture has been shown to travel about 20µm/s, including 
around 20-60 astrocytes per wave and affecting an area of about 50 to 300µm (Tian et al., 
2006).  Astrocytes can also detect changes in external environmental stimuli and set in 
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motion a series of intracellular responses via transient increases in internal Ca2+ levels 
(Verkhratsky et al., 1998).   
The information processing abilities of these cells using internal and external Ca2+ 
are diverse and relatively specific.  For example, hippocampal astrocytes can distinguish 
signaling from the specific axonal pathways and synaptic terminals of thousands of 
connections with extreme precision, assimilate multiple inputs that may serve to enhance 
and/or diminish Ca2+ signaling, and modulate spatiotemporal features of the signal (Perea 
and Araque, 2005).  The arrangement of astrocytes into distinct microdomains allows 
internal Ca2+ fluctuations to propagate throughout a syncytium of astrocytes via 
uncoupled gap junctions (Cornell-Bell et al., 1990b; Saez et al., 2003).  In this way, 
astrocytes can monitor, adjust, and respond to a variety of situations as an individual 
entity or as part of a functional unit.  Additionally, astrocyte-to-astrocyte signaling, as 
well as idirectional signaling between astrocytes and neurons using extracellular Ca2+ 
waves have been shown (Hassinger et al., 1996).  Briefly, synaptic release of several 
signaling molecules, including glutamate, activates astrocytes via various receptors, often 
ionotropic glutamate receptors or mGluRs.  In the case of mGluR-mediated activation, 
intracellular Ca2+ levels increase following the activation of a G-protein coupled pathway 
involving phospholipase C and inositol 1,4,5-trisphosphate (IP3), a signaling pathway that 
has multiple downstream effects (Hansson and Ronnback, 2003), including the release of 
glutamate and/or ATP that can bind P2X receptors on neighboring astrocytes and results 
in the further release of Ca2+ (Haydon and Carmignoto, 2006) (Figure 1.3d).  This 
activation and extracellular release of Ca2+ is directly influenced by the intensity of the 





Figure 1.3 Selected functions of astrocytes.  (a) Astrocytes respond to activity-driven 
increases in cerebral blood flow by procuring glucose from nearby vasculature via end 
foot-bearing processes that express GLUT 1 and 2.  (b) Astrocytes regulate pH through 
several processes, including the ion exchange and transport of K+ that is released during 
neuronal activity.  (c) S100β expression influences energy metabolism, calcium 
homeostasis, and cell growth and differentiation, including the degree of astrocytic 
process extension, in part, by regulating GFAP phosphorylation-dependent incorporation 
into the cytoskeleton.  (d) Glutamate activates various astrocytic receptors such as 
ionotropic glutamate receptors and mGluRs.  During mGluR activation, intracellular Ca2+ 
levels increase via a G-protein coupled pathway involving phospholipase C and IP3, a 
signaling pathway that can have multiple downstream cellular effects including the 
release of glutamate into the synapse.   
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c. Glutamate signaling.   
In addition to bi-directional modulation of synaptic activity via Ca2+, astrocytes 
can also respond to neuronal activation by releasing chemical transmitters, two of which, 
glutamate and the NMDA receptor co-agonist D-serine, are a part of a much bigger 
system involving astrocytes and glutamatergic functioning (Parpura et al., 1994; Schell et 
al., 1995; Montana et al., 2004; Mothet et al., 2005).   
Glutamate is the primary excitatory neurotransmitter in the brain, and astrocytes 
play a pivotal role in regulating excitatory neurotransmission via the control of 
transmitter synthesis, release, reuptake, and recycling.  Astrocytes can synthesize 
glutamate from glucose via the enzyme pyruvate carboxylase.  Since neurons do not 
express this enzyme, they are dependent upon astrocytes to provide glutamate both as a 
metabolic substrate and neurotransmitter signaling molecule (Hertz and Zielke, 2004).  
Astrocytes also transport glutamate from the synapse following excitatory release via 
high affinity excitatory amino acid transporters (EAATs) types 1, 2, 3, and 4 (Conti et al., 
1998; Sonnewald et al., 2002; Hu et al., 2003; Kim et al., 2003; Su et al., 2003) (Figure 
1.4a).  One fate of intracellular glutamate is conversion to glutamine by the astrocytic 
enzyme glutamine synthetase, an ATP-dependent enzyme detectable early in 
development in most species and in most tissue types that synthesize glutamine from 
glutamate (Suarez et al., 2002) (Figure 1.4b).   
Within the brain, glutamine synthetase is primarily located in the cytoplasm of 
astrocytes where, in addition to maintaining the glutamate-glutamine cycle, it is 
responsible for nitrogen metabolism and the detoxification of ammonia.  Furthermore, the 
activity of glutamine synthetase may modulate molecular correlates of memory, such as 
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long term potentiation.  One study showed that when methionine sulfoximine is used to 
block the actions of glutamine synthetase in chicks, the ability to consolidate memories 
was abolished, a process that was preventable when the chicks were administered 
glutamine (Gibbs et al., 1996).   
Glutamate that has been taken up into astrocytes from the synapse can be utilized 
by neurons both as metabolic fuel and as a transmitter molecule.  Glutamate, however, 
cannot be transported directly to neurons via the synapse because of the threat of 
excitotoxicity and inadvertent activation of glutamatergic receptors (Danbolt, 2001).  
Glutamate must first be converted to glutamine via glutamine synthetase before being 
transported to nearby neurons for subsequent release (Had-Aissouni et al., 2002) (Figure 
1.4b).  Once glutamine is relocated back into the presynaptic neuron, it may be converted 
to glutamate by the enzyme phosphate-activated glutaminase and packaged into synaptic 
vesicles by vesicular transporters (Bellocchio et al., 2000; Takamori et al., 2000) (Figure 
1.4c).  The presynaptic neuron then possesses stored neurotransmitter that may be 
subsequently released, thus completing a cycle that is crucial for the survival of neurons, 
maintaining synaptic efficacy and diversifying signaling.  
d. D-serine signaling.   
The emergence of D-serine as an endogenous modulator of the NMDA receptor 
and as a putative “gliotransmitter” molecule was rather recent.  Despite knowledge that a 
catabolizing enzyme for D-amino acids existed, proof of D-amino acids, aside from those 
related to dietary intake, was not available.  However, a D-configuration of serine was 
eventually shown to exist in physiologically relevant quantities in the mammalian brain 
(Hashimoto et al., 1992).  Subsequently, D-serine was found to bind with high affinity to 
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the glycine site on the NMDA receptor, with three times more potency than glycine 
(Matsui et al., 1995; Schell et al., 1995; Wolosker et al., 1999b).   
The release of D-serine from astrocytes in vitro has been shown to be mediated by 
AMPA, kainate, and mGluR glutamate receptors (Schell et al., 1995; Martineau et al., 
2005; Fujii et al., 2006).  Evidence for vesicular storage and release of D-serine (as well 
as for glutamate and ATP) has been demonstrated to occur in astrocytes by a SNARE 
(soluble N-ethylmaleimide-sensitive factor attachment protein receptor)-dependent 
mechanism (Coco et al., 2003; Bezzi et al., 2004; Mothet et al., 2005).  Release via gap-
junction hemichannels or transmembrane transport systems are other methods of ATP, 
glutamate, and possibly D-serine release (Ribeiro et al., 2002; Volterra and Meldolesi, 
2005).  Increases in synaptic glutamate, the result of neuronal activation, trigger the 
release of D-serine from astrocytes into the synapse where, along with glutamate, it binds 
to and activates the NMDA receptor (Martineau et al., 2005).  This role in NMDA 
receptor activation specifically implicates astrocytes and D-serine in NMDA receptor-
mediated LTP that occurs in learning and memory (Kelley et al., 2003; Martineau et al., 
2005).  For example, learning and memory deficits in rats that demonstrate age-related 
alterations in LTP can be rescued by the addition of exogenous D-serine (Mothet et al., 
2006).  Conversely, in the absence of astrocytes, cultured hippocampal neurons are 
unable to elicit NMDA receptor-induced LTP (Yang et al., 2003).   
D-serine appears to be removed from the synapse through a variety of transporters 
located on both neurons and astrocytes (Yamamoto et al., 2001; Javitt et al., 2002).  The 
degradation of D-serine is accomplished, in part, by D-amino acid oxidase (DAAO), an 
enzyme expressed in astrocytes in a regionally distinct manner, mainly in the cerebellum 
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and hindbrain, that converts D-serine to α-keto acid, ammonia, and H2O2 (Moreno et al., 
1999; Cook et al., 2002; Urai et al., 2002).  Further evidence of the importance of D-
serine to NMDA receptor activity is shown by the fact that in the presence of DAAO, 
NMDA receptor-mediated activation is inhibited (Hashimoto et al., 1993; Mothet et al., 
2000).  It is notable that the areas which express high levels of DAAO are relatively 
devoid of D-serine expression, which may suggest other regionally-specific methods of 
D-serine degradation.  
D-serine is synthesized by the enzyme serine racemase, a predominantly 
astrocytic, PLP-dependent enzyme that co-localizes with D-serine (Schell et al., 1995; 
Schell et al., 1997; Wolosker et al., 1999a; Miranda et al., 2000; Yasuda E, 2001) (Figure 
1.4d).  This enzyme has been proposed as the main regulator of both intra- and 
extracellular D-serine concentrations in the forebrain via conversion of L-serine to D-
serine following glutamate-induced activation of kainate and AMPA receptors and by an 
α, β-elimination reaction, respectively (Foltyn et al., 2005; Kim et al., 2005).  The α, β-
elimination of D-serine by serine racemase is the complement or perhaps competition to 
DAAO-mediated breakdown in the hindbrain.  Nitric oxide (NO) has been shown to play 
a role in determining which of these methods predominates at a given synapse, inhibiting 
serine racemase mediated breakdown of D-serine and enhancing that of DAAO (Shoji et 
al., 2006a, b).  Conversely, a feedback system for D-serine-mediated regulation of NO 
synthase, the synthesizing enzyme of NO, has also been proposed (Shoji et al., 2006a). 
Yeast-two hybrid experiments suggest that the activity of serine racemase may be 
modulated, at least in part, by its binding with glutamate receptor interacting protein 





Figure 1.4 An astrocyte-mediated glutamate cycle.  (a) Astrocytes transport glutamate 
from the synapse following excitatory release via high affinity EAAT1, 2, 3, and 4.  
Glutamate cannot be transported directly to neurons via the synapse because of the threat 
of excitotoxicity and inadvertent activation of glutamatergic receptors.  (b) One fate of 
intracellular glutamate is conversion to glutamine by the astrocytic enzyme glutamine 
synthetase.  (c) Once glutamine is relocated back into the presynaptic neuron, it may be 
converted to glutamate and packaged into synaptic vesicles by vesicular glutamate 
transporters (VGLUTs).  (d) The NMDA receptor co-agonist, D-serine, is synthesized by 
the enzyme serine racemase. 
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receptor activation and made available to bind serine racemase, which in turn stimulates 
increased D-serine production.  Another protein that interacts with serine racemase, 
possibly modulating its activity, is PICK1 (protein interacting with C-kinase) (Fujii et al., 
2006).  Both GRIP and PICK1 interactions with serine racemase occur via a PDZ protein 
interaction domain, but the effects of PICK1 binding are as yet unknown.  Recently, it 
was shown that NO can also alter serine racemase activity by removing ATP via S-
nitrosylation, a mechanism likely modulated by activation of the NMDA receptor 
(Mustafa et al., 2007).   
Until recently, the synthesis of D-serine by serine racemase was thought to be 
astrocyte specific.  More recent evidence shows that a subset of glutamatergic neurons 
also expresses this molecule, albeit in lesser quantities, in the cerebellum and hindbrain 
(Kartvelishvily et al., 2006; Williams et al., 2006).  Additionally, primary cultures of rat 
neurons have been shown to express serine racemase protein and transcript at relatively 
high levels (Yoshikawa et al., 2006).  However, cultured rat hippocampal neurons were 
unable to elicit NMDA receptor activation in the absence of astrocytes, even when 
supplemented with glial conditioned medium, suggesting that astrocytes are the primary 
source of D-serine in the brain (Yang et al., 2003).  The reported distribution of D-serine 
in the brain has also been revised recently.  Localization of D-serine containing astrocytes 
in the forebrain was thought to closely mirror that of the NMDA receptor.  However, D-
serine-expressing astrocytes have now been demonstrated in areas that express low levels 
of NMDA receptors, such as in white matter, opening up the possibility for as yet 
undiscovered functions of D-serine (Schell et al., 1997; Yasuda et al., 2001; Williams et 
al., 2006).  
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1.6.7 Morphology.   
Every astrocyte-mediated function discussed so far requires that astrocytes 
respond to the changing needs around them, and this is mediated by the ability of 
astrocytes to alter process morphology.  Astrocytes demonstrate considerable structural 
plasticity and will elongate processes to accommodate their environment, for example, by 
reaching toward blood vessels or extending processes in parallel with neuronal process 
extensions to monitor activity in adjacent synapses (Cornell-Bell et al., 1990a; Bushong 
et al., 2002).  This plasticity is made possible by Ifs, such as GFAP, which are 
incorporated into the cytoskeleton to influence process morphology.  GFAP molecules 
are often in a state of fluctuating polymerization and depolymerization.  The assembly or 
disassembly of these filaments is regulated by kinases that phosphorylate GFAP at the N-
terminus.  The incorporation of GFAP into the cytoskeleton is mediated by several 
different signaling molecules, including Ca2+, glutamate, and the calcium binding protein 
S100β (Rodnight et al., 1997; Kommers et al., 2002; Frizzo et al., 2004; Chang et al., 
2005).   
GFAP, arguably the most recognized cytoskeletal component of the astrocyte, is 
expressed throughout astrocytic processes and is used as the standard identifying marker 
for mature astrocytes in the CNS.  Although the entire functional repertoire of GFAP and 
other intermediate filament proteins is not well understood, research shows that changes 
in its expression levels influence not only astrocytic and neuronal structure and function, 
but also animal behavior, suggesting that GFAP plays an important role in modulating 
brain physiology.   
Mice devoid of GFAP due to a targeted deletion in utero develop and mature 
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normally, demonstrating normal astrocyte density and no compensatory upregulation of 
the IF vimentin (Pekny et al., 1995; McCall et al., 1996).  While the animals retain the 
ability to elicit a response to brain trauma by reactive gliosis, it is mediated by vimentin 
rather than GFAP.  Vimentin knock out mice (Vim-/-), on the other hand, demonstrate 
disorganized assembly of GFAP filaments, a phenomenon that seems to affect only 
subsets of astrocytes.  Gray matter astrocytes in the cerebellum of these mice were 
completely devoid of IFs and had abnormal morphology, while white matter astrocytes 
appeared normal and contained IFs (Galou et al., 1996).  Immunostaining primary 
astrocyte cultures of Vim-/- cells demonstrated reduced GFAP levels and other studoes 
revealed that GFAP mRNA levels were also significantly reduced.  While overall GFAP 
protein levels were normal, the soluble fraction of GFAP was significantly increased in 
Vim-/- cells.  Taken together, these results suggest that both the transcription and 
cytoskeletal assembly of GFAP in astrocytes, or in a subset of astrocytes, may be 
regulated by vimentin (Galou et al., 1996).   
When GFAP expression is decreased, astrocytes exhibit a profound loss of 
process extension.  Astrocytes typically respond to the presence of neurons by extending 
processes toward them; however, studies have shown that blocking GFAP expression 
with antisense mRNA in human astrocytoma cells prevented this process extension 
(Weinstein et al., 1991), and that this ability was restored when GFAP was re-introduced 
to the cell line (Chen and Liem, 1994).  Mice with disrupted GFAP expression have 
shorter astrocytic processes that are also smaller in diameter than those of wild type mice 
(McCall et al., 1996; Shibuki et al., 1996).  Functionally, changes to GFAP expression, 
and therefore to astrocyte process morphology, may impact homeostatic functions such as 
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metabolism and ion regulation. 
The survival and outgrowth of neurons has been shown to be under the influence 
of astrocytes (Goldberg and Barres, 2000).  Interestingly, the loss of GFAP and vimentin 
in transgenic mice has been shown to increase neuronal survival and outgrowth.  The loss 
of GFAP, but not vimentin, was shown to be responsible for the enhanced survival, a 
phenomenon mediated mainly by cell-to-cell contact and to a lesser extent by astrocytic 
releasing factors (Menet et al., 2001).  Other studies have shown that loss of GFAP in 
transgenic mice results in white matter abnormalities, which, like symptoms of 
schizophrenia, emerge in adulthood (Liedtke et al., 1996).  Recently, Alexander disease, a 
fatal, neurodegenerative condition, was found to be caused by missense mutations in 
GFAP (Brenner et al., 2001).  These mutations result in abnormal cytoplasmic 
aggregations of GFAP within the astrocyte called Rosenthal fibers (Perng et al., 2006).  
In addition to neurodegeneration and abnormal aggregates of GFAP, Alexander disease is 
also characterized by a dramatic loss of myelination (Johnson, 2002).  This suggests that 
astrocytes and more specifically GFAP expression can influence the survival and 
function of both neurons and oligodendrocytes.   
Other animal models have suggested a role for astrocytes and GFAP expression in 
synaptic plasticity.  Mice with disrupted GFAP expression exhibit important behavioral 
changes including impaired eyeblink conditioning, enhanced LTP, and reduced long term 
depression (LTD) in the cerebellum (McCall et al., 1996; Shibuki et al., 1996).  The 
mechanism by which this took place was unclear until several studies demonstrated that 
polymerization of GFAP into the astrocyte cytoskeleton is regulated by phosphorylation 
induced by type II mGluRs in the hippocampus and NMDA receptors in the cerebellum 
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(Kommers et al., 1999; Kommers et al., 2002; Battu et al., 2005).   
The role of cytoskeletal proteins as mediators of morphology has been expanded 
to also a role in glutamatergic transport.  It has been shown that GFAP is required for the 
trafficking and expression of glutamate transporters in both astrocytes and neurons.  
Decreased expression of EAAT1 and EAAT3 has been demonstrated in the hippocampus 
of GFAP-null mice (Hughes et al., 2004) (Table 1.1).  Additionally, the neuronal 
transporters in these mice were found to be localized in the cell body instead of within 
dendrites where they typically are expressed.  Increased expression of the astrocytic 
transporter EAAT2 was found in the cerebellum of GFAP-null mice, which may account 
for previous reports of deficient LTD in these animals.   
 
1.7 Glial dysfunction in schizophrenia 
A developmental hypothesis of schizophrenia suggests that when paired with 
genetic vulnerability, a perturbation of the developmental processes of neurogenesis, 
differentiation, migration, and/or synapse formation may contribute to the structural and 
functional defects that are often present in this illness.  However, neurons are not the only 
cell type affected either directly or indirectly when development is perturbed.  In fact, a 
postmortem gene array profile established that the genes most frequently altered in 
schizophrenia were related to glial function (Sugai et al., 2005).   
 
1.7.1 Oligodendrocyte abnormalities in schizophrenia.   
Oligodendrocyte-related abnormalities associated with psychosis have been 
documented in diseases of demyelination and in literature describing changes to brain 
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volume, cellular density and morphology, and gene expression in schizophrenia.  For 
example, diseases such as metachromatic leukodystrophy and velocardiofacial syndrome 
are characterized by loss of white matter and demyelination, and, like schizophrenia, 
result in psychosis during adolescence and early adulthood (Hyde et al., 1992; Walterfang 
M, 2005).  Abnormal expression of myelin-related proteins, such as myelin basic protein, 
has been discovered in the brains of patients with schizophrenia and depressed suicide 
victims (Honer et al., 1999).  Furthermore, in vivo imaging studies in schizophrenia 
reveal loss of white matter volume, which appears to be present at the first onset of 
illness that is associated with a predominance of negative symptoms (Buchanan et al., 
1998; Cannon et al., 1998; Sanfilipo et al., 2000; Pagsberg et al., 2007).   
At the cellular level, a study of postmortem brain tissue by Uranova et al. reported 
profound changes in oligodendrocytes that indicated that many of these cells were 
undergoing apoptosis or were already necrotic in schizophrenia (Uranova et al., 2001).  
Abnormalities included changes in cell morphology and key intracellular organelles such 
as nuclei, mitochondria, and endoplasmic reticulum, evidence of cell lysis near blood 
vessels, and loss or aberrant forms of myelination in the PFC and caudate nucleus.  More 
recently, a 25% reduction in oligodendrocyte density in layer VI of the PFC was reported 
in schizophrenia, suggesting that apoptosis and overall degeneration of these cells may be 
characteristic of this illness (Uranova et al., 2004).  Consistent with these data, another 
study demonstrated reduced oligodendrocyte density, as well as a reduction in 
oligodendrocyte to neuron ratio, in the thalamus in schizophrenia (Byne et al., 2006).   
There are aslo studies that have revealed altered gene expression of molecules that 
provide and maintain myelination in schizophrenia.  A study using DNA microarray 
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analysis showed that gene expression of five oligodendrocyte-related genes [myelin and 
lymphocyte protein (MAL), gelsolin, 2',3'-cyclic nucleotide 3'-phosphodiesterase (CNP), 
myelin-associated glycoprotein (MAG), transferrin, and Her3 (ErbB3)] were decreased in 
the PFC in schizophrenia (Hakak et al., 2001).  These results are supported by 
McCullumsmith et al., who found decreased transcript expression for several of the same 
proteins, including CNP, MAG, and transferrin, as well as the protein quaking, in white 
matter of the anterior cingulate cortex (ACC) in patients with schizophrenia 
(McCullumsmith et al., 2007).  Dracheva et al. recently reported decreased mRNA and 
protein expression of molecules related to oligodendrocyte function in the ACC and 
hippocampus but not in the putamen in schizophrenia, indicating that these changes occur 
in a region-specific manner (Dracheva et al., 2006).  New data are beginning to emerge 
which identify specific genes that may impart susceptibility to oligodendrocyte- and 
myelination-related dysfunction in schizophrenia.  For example, oligodendrocyte lineage 
transcription factor 2 (OLIG2), a key molecule in developing and maintaining white 
matter functionality, has been identified as one of several genes implicated in this illness 
(Georgieva et al., 2006).  Taken together, these data suggest that oligodendritic 
dysfunction is a prominent feature of the pathophysiology of schizophrenia.  Whether this 
dysfunction arises during development, is secondary to neuronal abnormalities, or is a 
combination of multiple factors is unclear.  Additional data suggest that other glial cells, 
such as astrocytes, may also play a role in this illness. 
 
1.7.2 Astrocyte abnormalities in schizophrenia.   
A developmental hypothesis for schizophrenia is a viable model; however, to 
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suggest that it would exclusively involve just one cell type, neurons, seems unrealistic.  
The involvement of astrocytes, especially in the two currently predominant hypotheses of 
schizophrenia, developmental and glutamatergic dysfunction, must be examined.   
Radial glia, the early glial progenitor cells in the brain play an important role in 
early brain development.  These cells regulate several processes, including neurogenesis, 
differentiation, and migration (Weissman et al., 2004; Gotz and Huttner, 2005).  Studies 
suggest that alterations in the structure and function of radial glia could have a profound 
impact on the developing brain.  For instance, early postnatal ablation of mouse brain 
astrocytes profoundly affects neuronal morphology, survival, and maturation (Delaney et 
al., 1996).  Furthermore, a model of disturbed radial glia in the developing mouse brain 
demonstrates that abnormally shaped and irregularly organized glial cells contribute to a 
malformed cortical lamina (Ueda et al., 1997).   The deleterious effects of ethanol on fetal 
brain development also appear to involve an impairment of radial glia function, which in 
turn disturbs neuronal migration (Guerri et al., 2001).  At later developmental stages the 
astrocytes derived from these radial glial cells are morphologically and functionally 
disturbed, which further impairs brain function.  Together these results confirm that 
malfunctioning radial glia can result in a compromised cortical lamina and that the 
already tenuous neurons that do survive may be further compromised by insufficient 
astrocyte support.   
Signaling molecules expressed by astrocytes, such as S100β, have been examined 
in schizophrenia as a marker of astrocytic integrity.  Multiple studies have provided 
evidence for increased S100β in the serum or cerebrospinal fluid (CSF) of patients with 
schizophrenia (Wiesmann et al., 1999; Lara et al., 2001; Rothermundt et al., 2001; 
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Schroeter et al., 2003; Rothermundt et al., 2004b; Rothermundt et al., 2004a; Schmitt et 
al., 2005; Rothermundt et al., 2007).  These increased serum and CSF levels have been 
interpreted as a marker of structural damage, perhaps reflecting cells that are leaking 
S100β into the periphery, and alternatively as a sign of increased astrocyte activation 
(Wiesmann et al., 1999).  On the other hand, increased S100β expression may occur due 
to genetic reasons, rather than being a result of the schizophrenia disease process.  A 
S100β gene haplotype associated with schizophrenia has been shown to be involved with 
increased S100β expression (Liu et al., 2005).  Another explanation for increased S100β 
levels in patients with schizophrenia may be treatment with antipsychotic medication.  
One study that compared recently medicated and non-medicated patients demonstrated 
that only medicated patients exhibited increased serum levels of S100β (Schroeter et al., 
2003).  However, increased S100β serum levels have also been demonstrated in 
individuals experiencing their first onset of the illness, never-before medicated patients, 
as well as in patients who were previously treated, but medication-free at the time of the 
study (Lara et al., 2001; Rothermundt et al., 2001; Steiner et al., 2006).  Moreover, there 
is evidence that antipsychotic treatment can normalize S100β levels in some individuals.  
One study showed that six weeks of antipsychotic treatment significantly reduced S100β 
levels in half of the patients, although the other patients maintained significantly elevated 
levels compared to the nonpsychiatrically ill comparison group (Rothermundt et al., 
2001).  These conflicting results suggest that S100β expression is variable in 
schizophrenia, and evidence suggests that differences in S100β expression may delineate 
a particular subset of individuals in this illness.  Multiple studies have shown a positive 
correlation between S100β levels and severity of thought disturbance and predominance 
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of negative symptoms in schizophrenia; positive symptoms, on the other hand, are not 
predictive of S100β levels (Lara et al., 2001; Rothermundt et al., 2001; Schroeter et al., 
2003; Rothermundt et al., 2004b; Rothermundt et al., 2004a).  Conversely, there is other 
evidence for a negative correlation between S100β levels and disease duration (Lara et 
al., 2001).  These data for abnormal sera and CSF S100β levels, as well as the tendency 
for these changes to accompany negative symptomology, suggest S100β is an astrocytic 
molecule that may contribute to brain dysfunction in schizophrenia.   
Additional support for the theory of disturbed astrocyte function playing a role in 
the pathophysiology of schizophrenia stems from the lack of gliosis in the brains of 
patients with this illness.  This factor has typically been used to argue for developmental 
origins and against degeneration or post-maturational changes in schizophrenia.  
However, a lack of gliosis may simply portray a system that is significantly compromised 
and unable to respond in its normal manner.  For instance, one postmortem study 
demonstrated that astrocyte-mediated gliosis in the brains of individuals with 
schizophrenia had a much weaker response to lobotomy-induced brain insult compared to 
a non-psychiatrically ill group (Niizato et al., 2001).  There is evidence for situations in 
which prenatal viral exposure (most likely paired with genetic predisposition) can result 
in a psychiatric condition without evidence of gliosis (Sawa et al., 2004).  Transgenic 
mice with glial cells selectively expressing Borna disease virus phosphoprotein (BDV-P) 
develop behavioral and structural brain abnormalities consistent with neurodevelopment 
insult without any evidence of gliosis (Kamitani et al., 2003).  
In direct contrast to gliosis, early studies of astrocyte-related pathology in 
schizophrenia reported the loss of astrocytes in several cortical areas already known to 
 47 
contain neuronal abnormalities, including the PFC, ACC, and motor cortex (Benes et al., 
1986; Stark et al., 2004).  Furthermore, localized astrocyte density reductions in layer VI 
of the ACC and layer V of the PFC suggest that some cortical regions demonstrate 
lamina-specific pathology in schizophrenia (Cotter et al., 2001; Cotter et al., 2002).  
Additionally, reports of altered astrocyte density around blood vessels in the PFC suggest 
a loss of astrocyte-mediated metabolic functioning in schizophrenia (Webster et al., 
2001).  These studies demonstrate regionalized astrocytic deficits and suggest that 
structural and functional abnormalities seen in schizophrenia may, in part, result from a 
loss of astrocytes.  
 
1.7.3 Astrocyteinvolvement in glutamate system abnormalities.   
Glutamate dysfunction is broadly implicated in schizophrenia; however, the 
majority of glutamatergic abnormalities reported in schizophrenia appear to target 
neurons.  Astrocytes play numerous roles vital to glutamatergic transmission.  As 
mentioned previously, a critical function of astrocytes at the glutamatergic synapse is the 
reuptake of glutamate, which is accomplished by high affinity EAATs.  The disruption of 
glutamate reuptake, either by increased or decreased expression of these transporter 
molecules, could impart grave consequences for neuronal signaling and survival.  Mice 
lacking the glutamate transporter GLT-1 (the equivalent of EAAT2 in humans) have been 
shown to exhibit increased extracellular glutamate levels and increased vulnerability to 
brain insult and excitotoxicity (Mitani and Tanaka, 2003) (Table 1.1).  In humans, 
decreased glutamate transport caused by polymorphisms in the promoter region of 
EAAT2 has been associated with increased neurodegeneration following stroke (Mallolas  
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Table 1.1 Altered expression of excitatory amino acid transporters in schizophrenia 
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et al., 2006).  In schizophrenia, there have been several studies that have document 
altered expression of astrocytic EAATs (Matute et al., 2005; Ohnuma et al., 1998; 
Ohnuma et al., 2000; Smith et al., 2001a).  In the context of schizophrenia-related 
glutamate hypofunction, it is notable that astrocytes can play a role in the down-
regulation of EAAT expression via treatment with antipsychotics.  Synaptic glutamate 
activity can closely regulate the expression of EAAT molecules in astrocytes (Watanabe 
et al., 1999).  This is accomplished, in part, by mGluRs and EAAT-interacting proteins, 
which have both been shown to be altered in schizophrenia (Ohnuma et al., 1998; Gupta 
et al., 2005; Huerta et al., 2006).   
Other roles of astrocytes in the glutamate synapse are bidirectional signaling with 
neurons and mediation of neuronal synchrony via NMDA receptors (Fellin et al., 2004).  
Consistent with these roles, astrocytes have been implicated in dysfunction of the NMDA 
receptor in schizophrenia.  Specifically, D-serine, an NMDA receptor co-agonist 
synthesized by astrocytes, has been implicated in the pathophysiology of schizophrenia.  
Recent studies document decreased levels of D-serine in the serum and CSF of patients 
with schizophrenia (Hashimoto et al., 2003; Bendikov et al., 2007).  Additionally, 
patients with schizophrenia who concurrently received D-serine and standard 
antipsychotic treatment showed improvement in positive and negative symptoms as well 
as in cognition (Tsai et al., 1998; Tsai et al., 1999; Heresco-Levy et al., 2005).  The 
prominent association of glutamatergic dysfunction in schizophrenia with D-serine also 
implicates the synthesizing enzyme serine racemase.  Recently, an allele for the gene 
encoding serine racemase was associated with schizophrenia that suggests reduced serine 
racemase expression can distinguishs a subtype of patients with paranoid schizophrenia 
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(Morita et al., 2007). 
Another molecule linking D-serine with NMDA receptor dysfunction is the 
catabolizing enzyme DAAO.  Several studies have found significant linkage between 
schizophrenia and genes that both encode as well as regulate D-amino acid oxidase, 
including D-amino acid oxidase activator (DAOA) (previously referred to in the literature 
as G72), and an associated gene, G30 (Chumakov et al., 2002; Korostishevsky et al., 
2004; Schumacher et al., 2004).  Alterations of these genes are consistent with a 
hypothesis of abnormal NMDA receptor activity in schizophrenia, as oxidation of D-
serine by DAAO has been shown to reduce NMDA receptor activity, while increased 
NMDA receptor activity has been shown to stimulate transcript expression of DAAO 
(Mothet et al., 2000; Yoshikawa et al., 2004; Almond et al., 2006). 
These data, together with studies demonstrating that gene expression changes in 
schizophrenia are predominantly comprised of those related to glia cell function, argue 
that astrocytes are compromised in schizophrenia, and furthermore, may be dynamically 
contributing to an already severely affected system. 
 
1.8 Conclusions 
There is a body of literature that points to a developmental hypothesis of 
schizophrenia.  Genetic and environmental factors may work together to dysregulate 
normal neurodevelopmental processes and thereby give rise to disorganized connectivity 
across several brain regions.  Furthermore, while this disturbed neural connectivity may 
only initially give rise to subtle functional and behavioral abnormalities, it may be 
particularly vulnerable to intense synaptic pruning that occurs during adolescence.  As a 
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result, since circuits were not functioning optimally to begin with, a dramatic reduction of 
synaptic connections may precipitate a sudden magnification of dysfunction and the 
emergence of schizophrenic symptomology.   
While the majority of studies to date have focused on neuronal pathology and 
possible perturbations of neuronal development in schizophrenia, more recent work 
points to developmental alterations that could also impact glial structure and function.  
Astrocytes provide a multitude of crucial functions in the brain and there is growing 
evidence to suggest that astrocytes have a contributing role in the pathophysiology of 
schizophrenia.  Examining the molecular components of astrocytes that facilitate brain 
function will help determine whether there is a relationship between the expression and 
function of astrocytes and the dysfunction seen in schizophrenia.  Deriving a disease 
pathway that involves altered expression and/or activity of molecules governing 
astrocyte-mediated brain function will require a reappraisal of the existing neuro-centric 
disease model of schizophrenia.  Consequently, the major aim of this dissertation 
research is to examine whether key structural and functional molecules expressed by 
astrocytes are altered in the brain in  schizophrenia, and, furthermore, to determine 
whether astrocytes contribute to glutamatergic dysfunction in schizophrenia.   
 
1.9 Goals of dissertation research 
I hypothesize that there is an astrocytic component to the pathophysiology of 
schizophrenia and that key structural and functional molecules expressed by astrocytes 
are abnormally expressed in this illness.  Previous research suggests that glutamatergic 
function that is prominent in schizophrenia may have an underlying astrocytic 
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component.  Furthermore, I hypothesize that schizophrenia may be characterized by a 
global astrocytic lesion.  This dissertation work is comprised of three sets of experiments 
designed to examine the transcript and protein expression of specific structural and 
functional astrocytic molecules in multiple brain regions, including the dorsolateral 
prefrontal, anterior cingulate, superior temporal, and primary visual cortices, as well as in 
the hippocampus.   
Chapters two and three will describe findings for the transcript and protein 
expression of GFAP, S100β, and glutamine synthetase, molecules linked to astrocyte 
structure and function.  Chapter three also details the protein expression of several of 
these molecules in haloperidol treated rats, to determine whether any expression changes 
found in postmortem studies could be attributed to a medication effect.  Chapter four will 
detail a multi-regional study of the expression of an enzyme only recently linked to 
schizophrenia, serine racemase.   
The ability of astrocytes to monitor and respond to changes in the environment 
depends, in part, upon the ability to alter process morphology.  Therefore, I hypothesize 
that cytoskeletal proteins such as GFAP and the molecules that regulate incorporation 
into the cytoskeleton, such as S100β, are abnormally expressed in schizophrenia.  The 
impetus for studying S100β, besides its role in regulating GFAP, comes from genetic 
studies implicating increased S100β expression in schizophrenia.  In addition, individuals 
with schizophrenia have altered S100β levels which positively correlate with symptom 
severity.  Surprisingly, in light of these factors linking S100β to schizophrenia, this 
protein has been relatively unexamined.  The study of GFAP expression in schizophrenia 
has already uncovered several abnormalities; however, only a limited number of brain 
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regions have been investigated.  My intention is to determine whether GFAP expression 
changes will replicate those already published, and to expand the existing literature to 
include several brain regions in which GFAP had not yet been examined. 
Alterations of multiple molecules involved in glutamatergic function have been 
demonstrated in schizophrenia.  Historically, studies have focused on neuronal 
dysfunction.  Despite the pivotal role of glutamine synthetase in maintaining the ongoing 
function and survival of neurons and astrocytes through a tightly regulated glutamate-
glutamine cycle, surprisingly few studies have examined this molecule in schizophrenia.  
Likewise, serine racemase, which modulates NMDA receptor function via the synthesis 
of D-serine, is an important molecule to study in an illness wrought with glutamatergic 
dysfunction.   
These molecules govern several overlapping functional aspects of astrocytes and 
alterations in their expression may span multiple brain regions.  Based on the patterns 
that emerge from these studies, we can begin to define the role of astrocytes in regional 
dysfunction in schizophrenia.  For instance, decreased expression of numerous molecules 
might indicate a global astrocytic lesion in schizophrenia, while, distinct regional 
expression changes could be indicative of the loss of function in a specific subset of 
astrocytes.  Ultimately, these studies will help determine whether astrocytes significantly 
contribute to schizophrenia, and, if so, delineate some of the specific regions affected and 




TRANSCRIPT EXPRESSION OF GFAP, S100β, AND GLUTAMINE 
SYNTHETASE IN THE DORSOLATERAL PREFRONTAL AND ANTERIOR 
CINGULATE CORTICIES IN SCHIZOPHRENIA 
 
2.1 Introduction 
As discussed previously, the recent understanding of the complexity of astrocyte 
involvement in brain function has lead to this cell type being implicated in psychiatric 
illnesses such as schizophrenia.  Several studies have found decreased astrocyte density 
in cortical areas compromised in schizophrenia, including prefrontal, anterior cingulate, 
and motor cortices (Benes et al., 1986; Cotter et al., 2001; Cotter et al., 2002; Stark et al., 
2004).  Evidence now suggests a role for those components of astrocytes involved with 
cytoskeletal integrity, signaling, and enzymatic activity in the pathophysiology of 
schizophrenia.   
As critical component of the astrocyte cytoskeleton, GFAP is expressed 
throughout cell processes and is used as a standard to identify mature astrocytes in the 
CNS.  The expression of GFAP can influence not only cellular structure and function, but 
also behavior (Weinstein et al., 1991; Shibuki et al., 1996), suggesting a role for this 
molecule in modulating brain physiology.  In schizophrenia, studies have shown 
decreases in phosphorylated isoforms of GFAP and a decreased immunoreactivity of this 
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protein (Rajkowska et al., 1998; Johnston-Wilson et al., 2000; Cotter et al., 2001; Knable 
et al., 2001; Webster et al., 2001; Rajkowska et al., 2002; Clark et al., 2006).  Despite 
numerous studies measuring protein expression, there is little published about the 
transcript expression of GFAP in schizophrenia.  
Like GFAP, the calcium binding protein S100β is a molecule expressed by 
astrocytes that influences cellular structure and function (Selinfreund et al., 1990; 
Whitaker-Azmitia et al., 1997; Winocura et al., 2001).  Due to its involvement in multiple 
signaling cascades, abnormal expression can impact energy metabolism, calcium 
homeostasis, and cell growth and differentiation.  Additionally, S100β modulates the 
ability of astrocytes to extend processes by regulating the incorporation of GFAP into the 
cytoskeleton (Garbuglia et al., 1999; Mbele et al., 2002).  Multiple studies have found 
increased S100β in the serum and CSF of patients with schizophrenia, and furthermore, 
these increases correlate with negative symptoms and illness duration (Wiesmann et al., 
1999; Lara et al., 2001; Rothermundt et al., 2001; Schroeter et al., 2003; Rothermundt et 
al., 2004b; Rothermundt et al., 2004a; Schmitt et al., 2005).  Although S100β has been 
studied in depth in peripheral fluids in schizophrenia, few reports on the brain expression 
of this molecule have been published.   
One of the major components of the pathophysiology of schizophrenia is 
glutamate system dysfunction (Goff and Coyle, 2001).  Studies have reported abnormal 
expression of molecules involved in the synthesis, transport, binding, reuptake, and 
recycling of glutamate--most of which are neuronal (Laruelle et al., 2003).  Astrocytes 
also mediate several aspects of glutamate functioning, as such an astrocytic component to 
glutamatergic dysfunction is emerging (Burbaeva et al., 1999; Anderson and Swanson, 
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2000; Ghose et al., 2004).  A tightly regulated glutamate-glutamine cycle is crucial to 
normal brain function (Hertz and Zielke, 2004).  Glutamine synthetase is an astrocytic 
enzyme that converts glutamate taken up from the synapse into glutamine.  This is 
important for a few reasons.  First, neurons depend on recycled glutamate as a metabolic 
intermediate and neurotransmitter molecule.  Second, excess glutamate in the synapse 
interferes with receptor activation and, at high levels, can result in excitotoxicity and cell 
death.  Studies have shown that thalamic transcript and cortical protein expression of 
glutamine synthetase are altered in schizophrenia (Burbaeva et al., 2003; Bruneau et al., 
2005).  Studies measuring glutamine synthetase transcript expression in schizophrenia 
have not yet been performed. 
Accumulating evidence suggests that structural and functional components of 
astrocytes may be compromised in schizophrenia.  I hypothesize that the expression of 
cytoskeletal, signaling, and enzymatic molecules expressed by astrocytes is altered in 
schizophrenia.  Accordingly, I used in situ hybridization to examine GFAP, S100β, and 
glutamine synthetase in two brain areas associated with complex cognitive functions that 
are often impaired in schizophrenia, the DLPFC and ACC. 
 
2.2 Methods 
2.2.1 Subjects  
Twenty seven subjects from the Mount Sinai Medical Center and Bronx Veterans 
Administration Medical Center were utilized for this study, consisting of eleven non-
psychiatrically ill individuals and sixteen patients with schizophrenia.  Consent for 
autopsy and use of brain tissue for research was obtained from the legal next of kin of 
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each donor.  Subjects were diagnosed with schizophrenia if the following criteria were 
fulfilled: 1) the presence of schizophrenic symptoms could be documented before age 40; 
2) the medical records contained evidence of psychotic symptoms and at least 10 years of 
psychiatric hospitalization with a diagnosis of schizophrenia; 3) a DSM-III-R diagnosis 
of schizophrenia was agreed upon by two experienced clinicians; and 4) neuropathologic 
examination did not reveal Alzheimer’s disease or other discernable neuropathologic 
abnormalities.  There were no significant differences between diagnostic groups for age, 
postmortem interval, sex, tissue pH, or hemisphere studied.  Brains were obtained at 
autopsy and the left hemisphere was cut coronally into 1 cm slabs and frozen. Fresh 
frozen blocks of DLPFC and ACC, as identified by gross anatomical landmarks, were 
cryostat-sectioned (14µm).  Sections were mounted on Superfrost Plus microscopic slides 
(Fisher Scientific, Pittsburgh, PA, USA) and stored at -80o C until use.  Two slides were 
studied per subject.  Within each region of cortex studied, the number of subjects varied, 
this information, as well as other subject characteristics are shown in Table 2.1.   
 
2.2.2 In situ hybridization.  
The expression of mRNA was measured by in situ hybridization using subclones 
generated by amplifying unique segments of GFAP (Genebank accession no. 
NM_002055; nucleotide coding region 1093-1311), S100β (NM_006272; 105-412), and 
glutamine synthetase (NM_002065, 214-530) from an unamplified human adult brain 
cDNA library (Edge Biosystems, Gaithersburg, MD, USA) and by Polymerase Chain 
Reaction (PCR).  PCR-amplified cDNA segments were extracted (QIAquick Gel 
Extraction Kit, Qiagen, Valencia, CA, USA), subcloned (Zero Blunt TOPO PCR cloning  
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Table 2.1 Subject characteristics for Mount Sinai and Bronx Veterans Administration 
Medical Centers cohort – transcript study 
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kit; Invitrogen, Carlsbad, CA, USA), and confirmed by nucleotide sequencing. 
Sense and antisense probes for in situ hybridization were synthesized using 100 µCi of 
dried [35S] UTP, 2.0 µl 5x transcription buffer (40mM Tris, 6mM MgCl2, 2mM 
spermidine,10mM NaCl, pH 7.9); 1.0µl each of 10mM ATP, CTP, and GTP; 1.0µg 
linearized plasmid DNA; 0.5µl RNAse inhibitor; and 1.5µl SP6 or T7 RNA polymerase.  
After incubation for two hours at 37˚C, 1.0µl DNAse (RNAse-free) was added and 
incubated for 15 minutes at room temperature.  [35S] Labeled cRNA was purified with 
spin columns (Micro Bio-Spin P-30 Tris Spin Columns, Bio-Rad Laboratories, Hercules, 
CA, USA), diluted to 100µl final volume, and 1.0µl of 1M dithiothreitol (DTT) was 
added to a final concentration of 0.01M. 
Sections were fixed with 4% (weight:volume) formaldehyde for one hour at room 
temperature.  Next, sections were rinsed three times in 2X SSC (300mM NaCl / 30mM 
sodium citrate, pH 7.2) and incubated on a stir plate in 0.1M triethanolamine, pH 8.0 / 
acetic anhydride, 1:400 (volume/volume) for ten minutes at room temperature.  Sections 
were then washed in 2X SSC for ten minutes at room temperature, and dehydrated 
though graded alcohols and air-dried.  [35S] labeled riboprobe (3-5x106 cpm) was applied 
in 80µl of 50% formamide buffer (50% formamide, 10% dextran sulfate, 3X SSC, 50mM 
Na2HPO4, pH 7.4, 1X Denhardt’s solution, 100µg/ml yeast tRNA) with 0.1% of 1M DTT 
per each slide.  The slides were then covered with glass coverslips and stored in 
humidified chambers saturated with 50% formamide at 55˚C overnight.  The next day, 
the cover slips were removed and the sections were washed in 2X SSC for two minutes at 
room temperature, 2X SSC for ten minutes at room temperature, and then incubated with 
RNAse A (200mg/ml in 10mM Tris, pH 8.0 / 0.5M NaCl) at 37˚C for 30 minutes.  Slides 
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were then washed at room temperature two times for ten minutes in 2X SSC, ten minutes 
in 1X SSC, five minutes in 0.5X SSC, for 30-90 minutes in 0.1X SSC at 55˚C and ten 
minutes in 0.1X SSC at room temperature.  The sections were then dehydrated in graded 
alcohol solutions and air-dried.  Finally, the slides were placed in X-ray cassettes, 
apposed to Kodak BioMax MR autoradiographic film (Eastman Kodak Co., Rochester, 
NY, USA) and developed after six days (GFAP), nineteen days (S100β), or four days 
(glutamine synthetase). 
 
2.2.3 Data analysis.  
Images of each slide were captured with a CCD based imaging system using 
Scion Imaging software 4.0.3 (Scion Corporation, Fredrick, MD, USA).  Each transcript 
showed a distinct pattern of laminar distribution across the cortical thickness, and gray-
scale values were obtained from bands with densities different from adjacent bands 
(isodense bands).  Isodense bands did not correspond exactly with traditionally defined 
cortical layers.  Gray scale values from isodense bands were corrected for tissue 
background, and then converted to optical density (OD). OD values were converted to 
amount of radioactivity bound (nCi/g) determined from calibrated [14C] microscale 
standards (Amersham Biosciences, Piscataway, NJ, USA) (Miller, 1991).  The amount of 
bound probe was expressed as concentration of target mRNA per gram of tissue (fmol/g) 
by taking into account the specific activity of [35S] and the number of uridine residues in 




2.2.4 Statistical analysis.  
Statistical analysis was performed using factorial analysis of variance (ANOVA) 
with diagnosis and isodense bands as categorical independent variables.  In cases where 
age, postmortem interval (PMI), or pH was found to correlate significantly with a 
dependent variable, analysis of covariance (ANCOVA) was used.  For all tests  α = 0.05. 
 
2.3 Results 
I used in situ hybridization to measure transcript expression of three astrocytic 
molecules: GFAP, S100β, and glutamine synthetase in the DLPFC and ACC.  Sense and 
antisense probes were synthesized and tested, and only antisense probes produced 
specific labeling.  I detected each of the three molecules in each brain region (Figure 2.1). 
 
2.3.1  GFAP transcript expression. 
Transcript expression of GFAP in the DLPFC and ACC was heterogeneously 
distributed across cortical lamina, exhibiting four isodense bands in the gray matter and 
distinct labeling in white matter (Figure 2.1a, b).  In the DLPFC, there were no 
associations between GFAP expression and age, PMI, or pH.  I found a main effect for 
diagnosis using ANOVA, which revealed that GFAP transcript was significantly 
decreased in the DLPFC in schizophrenia (F(1, 87) = 3.98; p < 0.05) (Figure 2.2a).  In the 
ACC, I detected an association between GFAP expression and age (r = 0.25; p < 0.01).  
Using ANCOVA, I found a main effect for diagnosis for increased GFAP expression in 
schizophrenia (F(1, 96) = 11.97; p < 0.01) (Figure 2.2b).  There was no diagnosis by 





Figure 2.1 GFAP, S100β, and glutamine synthetase mRNA expression in the DLPFC 
and ACC.  Transcript expression of astrocytic molecules in the DLPFC and ACC of 
representative subjects with schizophrenia and a comparison group: GFAP (a, b), S100β 
(c, d), and glutamine synthetase (e, f) mRNAs.  Between two and four isodense bands 
were identified in the gray matter, and labeling in the white matter (wm) was also noted, 








Figure 2.2 Transcript expression of astrocytic molecules in schizophrenia.  Graphs 
depict transcript expression (fmol/g) in the DLPFC and ACC for GFAP (a, b), S100β (c, 
d), and glutamine synthetase (e, f) analyzed by diagnosis (comparison group and 
schizophrenia).  GFAP was decreased in the DLPFC (F(1, 87) = 3.98; *p < 0.05) and 
increased in the ACC (F(1, 96) = 11.97; **p < 0.01) in schizophrenia. 
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Given a past literature on the effects of normal aging on GFAP expression, I 
performed a secondary analysis examining the effect of age on GFAP mRNA expression  
in the DLPFC and ACC (Figure 2.3).  In the DLPFC, there was no significant effect for 
age on GFAP expression when all subjects were pooled (Figure 2.3a).  When I separated 
the subjects based on diagnosis there was a significant effect for age on GFAP expression 
in the comparison group (r = 0.40, p < 0.05), but not in schizophrenia (Figure 2.3a).  
There was a significant effect for age on GFAP expression in the ACC when all subjects 
were analyzed together (r = 0.25, p < 0.01) (Figure 2.3b).  This effect remained 
significant for the comparison group, but not for schizophrenia when groups were 
analyzed separately (r = 0.42, p < 0.01) (Figure 2.3b). 
 
2.3.2 S100β  transcript expression.   
The transcript expression of S100β in the DLPFC and ACC was heterogeneously 
distributed across cortical lamina and exhibited labeling in three isodense bands in the 
gray matter, and white matter labeling was also apparent (Figure 2.1c, d).  In the DLPFC, 
I detected a significant association between age (r = 0.28; p < 0.05) and PMI (r = -0.40; p 
< 0.01) and S100β expression.  I did not find a main effect for diagnosis in the DLPFC 
using ANCOVA (Figure 2.2c).  In the ACC, I detected an association between age (r = 
0.54; p <0.01) and PMI (r = -0.27; p < 0.05) and S100β transcript expression.  ANCOVA 
revealed a trend for decreased S100β transcript in the ACC in schizophrenia (F(1, 81) = 
3.21; p = 0.077) (Figure 2.2d).  There was no diagnosis by isodense band interactions in 





Figure 2.3 Bivariate plots of GFAP mRNA expression (fmol/g) versus age.  
Regression lines are shown for schizophrenia and comparison subjects plotted separately, 
as well as pooled.  (a) In the DLPFC, there was a significant effect for age on GFAP 
expression in the comparison group (*p < 0.05).  (b) In the ACC, there was an effect for 
age on GFAP expression when all subjects were analyzed together (**p < 0.01), as well 
as for the comparison subjects alone (*p < 0.005). 
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2.3.3 Glutamine Synthetase transcript expression.   
I detected glutamine synthetase transcript expression in two isodense bands in 
gray matter, and white matter labeling was also present (Figure 2.1e, f).  Correlation 
analysis did not reveal an association between glutamine synthetase expression, age, and 
PMI in the DLPFC or ACC.  Using ANCOVA, there was no effect for diagnosis and no 
diagnosis by isodense band interaction for glutamine synthetase expression in cortical 
area (Figure 2.2e, f).   
 
2.4 Discussion 
I tested the hypothesis that structural and functional components of astrocytes are 
compromised in schizophrenia by examining the transcript expression of the cytoskeletal, 
signaling, and enzymatic molecules (GFAP, S100β, and glutamine synthetase) in the 
DLPFC and ACC.  GFAP, an astrocytic intermediate-filament protein and component of 
the astrocytic cytoskeleton important for cellular structure and function, was decreased in 
the DLPFC.  Decreased transcript expression in the DLPFC, particularly in the context of 
a literature showing deficits in GFAP protein expression in schizophrenia could be due to 
a loss of astrocytic activation, process branching, and/or cellular density (Rajkowska et 
al., 1998; Johnston-Wilson et al., 2000; Cotter et al., 2001; Knable et al., 2001; Webster 
et al., 2001; Rajkowska et al., 2002; Clark et al., 2006).  
In the ACC of the same subjects, I found a significant increase in GFAP mRNA 
expression, indicating that GFAP is differentially regulated in frontal cortical regions.  
This finding is in contrast to the only other report on GFAP transcripts in the ACC in 
schizophrenia, which found decreased expression (Webster et al., 2005).  It is unlikely 
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that this increase I observed is due to enhanced activation of astrocytes, as reactive gliosis 
has not been described in this illness (Arnold et al., 1996; Falkai et al., 1999; Damadzic et 
al., 2001).  This increase is more likely a compensatory upregulation, perhaps in response 
to loss of astrocytes as has been reported previously in the ACC (Cotter et al., 2001).  I 
hoped to determine whether these abnormalities were due to transcript changes in 
individually identified cells, so I emulsion-dipped and processed the slides for cell-level 
studies of mRNA expression.  Although our laboratory has successfully used this 
technique in the past to identify neuronal transcripts at a cellular level, I was unable to 
consistently detect expression of this and other astrocytic molecules above background 
levels.  The relatively small size of astrocytes and extended process branching beyond the 
cell soma likely contributed to the inability to complete cell-level studies (Kohama et al., 
1995).   
Both GFAP mRNA and protein expression have been shown to routinely increase 
with age (Hansen et al., 1987; Nichols et al., 1993; Kohama et al., 1995; Yoshida et al., 
1996; David et al., 1997).  These age-related increases are thought to occur without an 
accompanying increase in astrocyte cell density (Nichols et al., 1993; Kohama et al., 
1995).  I did not detect any significant correlations between GFAP expression and age in 
the DLPFC when I analyzed all of the subjects pooled together.  However, I found that 
when grouped by diagnosis, GFAP expression in the comparison subjects positively 
correlated with age, which is consistent with earlier reports.  In contrast, GFAP 
expression was not correlated with age in schizophrenia.  This suggests that my finding 
of decreased GFAP in the DLPFC in schizophrenia is likely illness-related, as it occurs 
despite evidence of age-related increases in comparison subjects.  In the ACC, I found a 
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positive correlation between GFAP expression and age in both the pooled subjects and 
the comparison group alone.  Although this correlation was limited to the comparison 
group, GFAP expression was significantly increased in schizophrenia.  Reports of 
increased GFAP expression in schizophrenia are rare, however, one study found increase 
protein expression in elderly patients with schizophrenia also exhibiting dementia 
(Arnold et al., 1996).  This, taken with my present data in elderly subjects, suggests that 
GFAP expression varies not only by region and diagnosis, but may also delineate 
subgroups of persons with schizophrenia particularly associated with advanced age and 
end stage schizophrenia.  Supporting this hypothesis, several studies that have used 
younger subjects found GFAP expression unchanged in schizophrenia, although most of 
these studies did not seek to examine the effects of age on GFAP expression (Perrone-
Bizzozero et al., 1996; Karson et al., 1999; Fatemi et al., 2004; Dean et al., 2006). 
Recently, a study finding increased GFAP immunoreactivity in the prefrontal cortex was 
published (Toro et al., 2006).  However, since these results were drawn from the 
combined analysis of tissue from multiple Brodmann areas it is difficult to reconcile with 
my data given the region-specific differences in GFAP expression that I noted.   
A potentially confounding variable is that the majority of the schizophrenia 
subjects were chronically treated with typical antipsychotic medications.  Typical 
antipsychotics predominantly act at D2-like dopamine receptors.  Ligand binding data 
from rodent, primate, and human brains indicate that approximately 35% of cortical D2 
receptor binding may be associated with astrocyte expression (Khan et al., 2001).  
Nonetheless, double immunofluorescence labeling for c-fos and GFAP in rats astrocyte 
activation (Ma et al., 2003).  Increased glial density has been reported in primates 
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chronically treated with typical antipsychotics (Selemon et al., 1999).  However, studies 
of elderly patients with schizophrenia do not find increased astrocyte density as the result 
of chronic antipsychotic treatment (Nishioka and Arnold, 2004).  A recent study revealed 
a correlation between GFAP protein expression in the prefrontal cortex and cumulative 
lifetime dose of antipsychotics (Toro et al., 2006).  The effect of medication on GFAP 
expression remains unresolved.  While it is possible that my findings of altered GFAP 
expression are secondary to treatment with medications, it seems unlikely given that I 
found changes in opposite directions in DLPFC and ACC.   
I also measured transcript expression of the calcium binding protein S100β.  
S100β has been examined in schizophrenia and other psychiatric disorders as a marker of 
astrocytic integrity.  Recently, cortical transcript and protein expression of S100β was 
described; although changed in bipolar disorder, this molecule was found to be unaltered 
in schizophrenia (Dean et al., 2006).  Consistent with this study, I found S100β mRNA 
levels unchanged in the DLPFC and ACC in schizophrenia.  These results do not 
necessarily conflict with other data finding increased S100β in serum and CSF of patients 
with schizophrenia (Wiesmann et al., 1999; Lara et al., 2001; Rothermundt et al., 2001; 
Schroeter et al., 2003; Rothermundt et al., 2004b; Rothermundt et al., 2004a; Schmitt et 
al., 2005).  One hypothesis is that increased S100β in these fluids is a sign of damaged 
cells leaking the protein.  This would not necessarily coincide with changes in transcript 
expression in the brain, however.  One could speculate that treatment with antipsychotic 
medication could affect the expression of S100β, but increased S100β is found in sera 
and CSF of first time, unmedicated patients with schizophrenia.  Furthermore, increased 
treated with haloperidol did not show co-localization, suggesting a lack of antipsychotic-
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induced S100β persists following antipsychotic treatment; therefore, medication-related 
changes to peripheral S100β seem unlikely (Rothermundt et al., 2001; Rothermundt et 
al., 2004a; Schmitt et al., 2005).  A predictive factor for increased S100β in sera and CSF 
is a predominance of negative symptoms (Rothermundt et al., 2001; Schroeter et al., 
2003; Rothermundt et al., 2004a).  It is unclear whether cortical S100β expression is 
associated with any specific characteristics of this illness or whether it is affected by 
antipsychotic treatment.   
Finally, I measured the astrocytic enzyme glutamine synthetase.  Previously, our 
laboratory found increased glutamine synthetase transcript expression in the thalamus in 
a similar group of subjects (Bruneau et al., 2005).  In the present study, I did not detect 
any changes in either of the cortical regions studied.  In light of these results, transcript 
expression of this molecule, like GFAP, appears to be affected regionally rather than 
globally in this illness.  So far, none of the published studies of glutamine synthetase 
expression in schizophrenia have found changes that can be related to medication 
(Burbaeva et al., 2003; Toro et al., 2006) and there are no studies directly testing the 
effect of antipsychotics on this enzyme. 
This study examined structural and functional components of astrocytes including 
cytoskeletal, signaling, and enzymatic molecules in schizophrenia.  I found that GFAP, a 
molecule crucial for maintaining normal astrocyte structure and function is abnormally 
expressed in both the DLPFC and the ACC.  Although further work is needed to decipher 
whether these changes are associated with altered cell density, diminished process 
extension, or compensatory mechanisms secondary to this illness, altered expression of 
GFAP suggests that there are abnormalities in astrocytes that contribute to cortical 
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dysfunction in schizophrenia.  
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CHAPTER 3 
CORTICAL EXPRESSION OF GLIAL FIBRILLARY ACIDIC PROTEIN AND 
GLUTAMINE SYNTHETASE IS DECREASED IN SCHIZOPHRENIA  
 
3.1 Introduction 
As discussed in chapter one, alterations in astrocyte density, function and gene 
expression in schizophrenia suggest a role for these cells in the pathophysiology of this 
illness.  Astrocytes are connected to multiple synapses, blood vessels, and multiple types 
of cells by extensive process branching.  This enables astrocytes to support the metabolic 
needs of neurons, regulate extracellular ions, and facilitate cell to cell communication and 
neuroplasticity through the release of signaling molecules (Cornell-Bell et al., 1990b; 
Charles et al., 1991; Parpura et al., 1994; Schell et al., 1995; Allen and Barres, 2005).  
Due to the extensive role of astrocytes in brain physiology, changes to critical 
components of astrocytes involving structure and function may underlie brain 
dysfunction in schizophrenia.   
Studies reporting decreased density of astrocytes in cortical regions known to be 
compromised in schizophrenia, including prefrontal, anterior cingulate, and motor 
cortices (Benes et al., 1986; Cotter et al., 2002; Stark et al., 2004), as well as studies 
measuring the response of astrocytes to mechanical injury suggest an underlying 
vulnerability of this cell type in schizophrenia (Niizato et al., 2001).   
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Glutamatergic dysfunction has been widely reported in schizophrenia (Goff and 
Coyle, 2001).  Astrocytes orchestrate a series of events critical to normal glutamate 
function, and therefore are hypothesized in this dysfunction.  Within the glutamatergic 
synapse, presynaptic neurons package glutamate into vesicles for release into the synapse 
where it may bind to and activate receptors found on pre- and postsynaptic neurons and 
astrocytes (Hollmann and Heinemann, 1994; Bellocchio et al., 2000; Takamori et al., 
2000).  The subsequent removal of glutamate from the synapse, an event critical to 
regulating synaptic activity and preventing excitotoxicity, is accomplished primarily by 
astrocytes which express high affinity EAATs types 1, 2, 3, and 4 (Conti et al., 1998; 
Sonnewald et al., 2002; Hu et al., 2003; Kim et al., 2003).  Once recovered by astrocytes, 
glutamate may be converted to glutamine by the enzyme glutamine synthetase, and 
subsequently transported back to the presynaptic neuron for use as a metabolic substrate 
or transmitter molecule (Rothman et al., 1999).  The central role of glutamine synthetase 
in regulating a glutamate-glutamine cycle makes it a high yield target for investigating 
glutamate dysfunction in schizophrenia.   
The role of astrocytes in normal brain functioning is made possible, in part, by 
extensive process branching.  Astrocyte processes contain the cytoskeletal molecule 
GFAP, which when immunohistochemically labeled is used as a measure of cell density.  
The assembly of GFAP subunits into a functional cytoskeleton facilitates process 
extension that allows astrocytes to respond to changes in the microenvironment and 
contribute to synaptic plasticity (Rodnight et al., 1997; Ullian et al., 2001; Ullian et al., 
2004; Allen and Barres, 2005).  In vivo and in vitro experiments of altered GFAP 
expression demonstrate that loss of this cytoskeletal protein leads to decreased branching, 
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prevention of normal synaptic functioning, disruption of myelination, and aberrant 
behavior (Weinstein et al., 1991; Chen and Liem, 1994; Liedtke et al., 1996; McCall et 
al., 1996; Shibuki et al., 1996).  Abnormal assembly of the cytoskeleton caused by 
mutations in GFAP, as seen in Alexander disease, may lead to neurodegeneration and 
premature death (Mignot et al., 2004; Perng et al., 2006).  Since GFAP is necessary for 
cytoskeletal integrity and process branching, abnormalities in GFAP expression could 
lead to marked dysfunction. 
Astrocytes express molecules that are critical to normal brain function, including 
enzymes involved in the glutamate-glutamine cycle and cytoskeletal proteins which 
enable branching of astrocytic processes.  Abnormal expression of these molecules may 
be a factor in the pathophysiology of schizophrenia.  I hypothesize that glutamine 
synthetase and GFAP protein are abnormally expressed in this illness.  I measured these 
molecules in an elderly cohort with schizophrenia and a non-psychiatrically ill 
comparison group using Western blot analysis in the DLPFC, ACC, STG, PVC, and 
hippocampus.   
 
3.2 Methods 
3.2.1 Acquisition and processing of human brain tissue 
Fifty subjects from the Mount Sinai Medical Center and Bronx Veterans 
Administration Medical Center were utilized for this study, consisting of 27 non-
psychiatrically ill individuals and 23 patients with schizophrenia (Table 3.1).  Consent for 
autopsy and use of brain tissue for research was obtained from the legal next of kin of 
each donor.  Subjects were diagnosed with schizophrenia if the following criteria were  
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Table 3.1 Subject characteristics for Mount Sinai and Bronx Veterans Administration 
Medical Centers cohort – protein study  
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fulfilled: 1) the presence of schizophrenic symptoms could be documented before age 40; 
2) the medical records contained evidence of psychotic symptoms and at least 10 years of 
psychiatric hospitalization with a diagnosis of schizophrenia; 3) a DSM-III-R diagnosis 
of schizophrenia was agreed upon by two experienced clinicians; and 4) neuropathologic 
examination did not reveal Alzheimer’s disease or other discernable neuropathologic 
abnormalities.  
Brains obtained at autopsy were divided mid-sagittally at the time of extraction.  
The right half was fixed in 4% formaldehyde and used for neuropathological 
characterization.  The left half was sectioned in 6-8 mm coronal slabs, snap-frozen, and 
stored at –80oC.  The areas of interest were identified by gross anatomical landmarks and 
dissected from the frozen slabs from the following areas: dorsolateral prefrontal cortex, 
primary visual cortex, superior temporal gyrus, anterior cingulate cortex, and 
hippocampus (Dracheva et al., 2004; Katsel et al., 2005; Dracheva et al., 2006).  
Dissected, never-thawed tissues were pulverized at –190oC into a fine powder and 
aliquoted into individual Eppendorf tubes, and stored at –80oC.   
 
3.2.2 Acquisition and processing of rodent brain tissue 
Twenty-two adult, male Sprague-Dawley rats (250g) were housed two-three to a 
cage, with food and water ad libitum.  Animals were treated with daily intramuscular 
injections of haloperidol dissolved in dimethyl sulfoxide (DMSO) (Fisher Scientific, Fair 
Lawn, NJ, USA) (1 mg/kg/day, n=11), or vehicle (DMSO) (n=11) for 29 days.  Twenty-
four hours after the last injection, the animals were sacrificed and brains were 
immediately removed, dissected, and frozen in isopentane.  The frontal, cingulate, 
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occipital, and temporal cortices, and hippocampus were dissected according to The Rat 
Brain in Stereotaxic Coordinates (Paxinos and Watson, 1986).  The brains were stored at 
−80°C until assayed.  All animal experiments were approved by the University 
Committee on the Use and Care of Animals at the University of Michigan and were 
performed according to the guidelines for The Care and Use of Laboratory Animals of 
the National Institutes of Health.  
 
3.2.3 Tissue preparation 
Tissue specimens (human 50mg, rodent 20mg) were homogenized in 5mM Tris–
HCl (pH 7.4), containing Complete, mini, EDTA-free protease inhibitor cocktail tablets 
(Roche Applied Science, Indianapolis, IN, USA) (1 tablet/10mls) for 30 seconds with a 
PowerGen 125 homogenizer (Fisher Scientific International, Inc., Hampton NH, USA).  
Total protein concentration was determined with a BCA Protein Assay Kit (Pierce 
Biotechnology, Inc., Rockford IL, USA), and homogenates were stored at −80oC.   
 
3.2.4 Western blot analysis 
Samples were prepared by combining tissue homogenate with sample buffer 
(62.5mM Tris-HCl, 20% glycerol, 2% sodium dodecyl sulfate, 5% β-mercaptoethanol, 
pH 6.8) and heated at 95oC for four minutes.  Samples were then loaded onto pre-cast 
10% polyacrylamide Tris-HCl gels (Bio-Rad) in duplicate (20µg protein/well) and run in 
SDS/Tris/glycine buffer (25mM Tris-HCl, 192mM glycine, 0.1% SDS, pH 8.3) at 130 
mV for about one hour.  Following transblotting to nitrocellulose membranes in Tris-
glycine buffer (25mM Tris, 192mM glycine, pH 8.3), blots were blocked with powdered 
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milk in 5% TBS with 0.01% Tween-20 (TBST) (Fisher Scientific, Fair Lawn, NJ, USA) 
(pH 7.4) for one hour at room temperature and then agitated with mouse anti-glutamine 
synthetase monoclonal antibody (BD Biosciences, San Diego, CA) (1:1000), or mouse 
anti-glial fibrillary acidic protein monoclonal antibody (1:500,000) (Chemicon 
International, Temecula, CA, USA) in 5% powdered milk in TBST for two hours.  Blots 
were washed four times in TBST and incubated with a horseradish peroxidase-coupled 
goat anti-mouse secondary antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, 
USA) (1:5000) for two hours on a shaker at room temperature.  Following four washes in 
TBST and two washes in distilled water, enhanced chemiluminescence (ECL) was used 
for detection.  Blots were saturated with ECL reagent (Amersham, Piscataway, NJ, 
USA), covered in plastic wrap and exposed to ECL film (Amersham, Piscataway, NJ, 
USA).  Film was developed and digitally captured with a CCD based imaging system 
using Scion Imaging software 4.0.3.  Gray scale values were obtained for protein bands at 
the expected molecular weights, membrane background was subtracted, and the adjusted 
gray scale values from duplicate samples in adjacent lanes were averaged and converted 
to optical density.  Membranes were stripped and re-blotted for β-Tubulin (Upstate, lake 
Placid, NY, USA) as a loading control, and the mean optical density ratio of glutamine 
synthetase or GFAP/β-Tubulin was used for data analysis. 
 
3.2.5 Statistical Analysis 
Statistical analysis was performed with Statistical analysis was performed using 
Statistica software (StatSoft, Tulsa, OK).  Analysis of variance (ANOVA) with diagnosis 
as the independent variable and mean optical density ratio as the dependent variable was 
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used.  In cases where age, postmortem interval (PMI), or pH were found to significantly 
correlate with a dependent variable, analysis of covariance (ANCOVA) was used.  For all 
tests  α = 0.05. 
 
3.3 Results 
3.3.1 Protein expression of glutamine synthetase and GFAP in Schizophrenia 
I used Western blot analysis to measure the expression of glutamine synthetase 
and GFAP in the DLPFC, ACC, STG, PVC, and hippocampus.  Using antibodies specific 
for these molecules, I detected prominent bands at the expected molecular weights of 45 
kDa for glutamine synthetase, and 51 kDa for GFAP (Figure 3.1).   
Regression analysis showed no associations between glutamine synthesis 
expression and age, postmortem interval or pH in any of the areas examined.  Using 
ANOVA, I found a main effect for diagnosis for glutamine synthetase expression in the 
STG (F(1, 30) = 6.44; p = 0.02) and ACC (F(1, 30) = 6.99; p = 0.01) (Figure 3.2), but not 
in the DLPFC, PVN, or hippocampus.  Glutamine synthetase expression in the STG was 
reduced by 32% in schizophrenia versus the comparison group.  In the ACC, there was a 
19% decrease in the expression of glutamine synthetase in schizophrenia.   
Regression analysis showed no associations between GFAP expression and age, 
postmortem interval or pH in the DLPFC, ACC, or PVC.  In the STG and hippocampus, 
there was an association between GFAP expression, age, and PMI (age: r = 0.443, p = 
0.003; PMI: r = 0.465, p = .0002), and hippocampus (age: r = 0.329, p = 0.041; PMI: r = 
0.409, p = 0.009).  Using ANCOVA, I did not detect an effect for diagnosis on GFAP 





Figure 3.1 Western blots of astrocytic molecules from representative subjects with 
schizophrenia and a nonpsychiatrically ill comparison group.  Blots show protein 
expression of (a) glutamine synthetase, and (b) GFAP in the DLPFC, PVC, STG, ACC, 








Figure 3.2 Glutamine synthetase protein expression in the DLPFC, PVN, STG, 
ACC, and hippocampus.  Protein expression was analyzed by diagnosis (comparison 
group and schizophrenia).  Glutamine synthetase was significantly decreased in the STG 






Figure 3.3 GFAP protein expression in the DLPFC, PVN, STG, ACC, and 
hippocampus.   Protein expression was analyzed by diagnosis (comparison group and 
schizophrenia).  Expression is shown as mean OD ratio for β-Tubulin with GFAP.  There 




diagnosis for GFAP expression in the ACC (F(1, 43) = 5.68; p = 0.02), but not in the 
DLPFC, or PVC (Figure 3.3).  The expression of GFAP in the ACC was reduced in 
schizophrenia by 13% versus the comparison group.   
I performed regression analysis to examine the effect of age on protein expression 
of glutamine synthetase and GFAP in these five brain regions.  I did not detect a 
significant effect for age on glutamine synthetase expression in any of the regions 
studied, whether data were analyzed by diagnosis or pooled (data not shown).  GFAP 
expression was not associated with age in any of the brain areas when subjects from each 
diagnostic group where analyzed separately.  When data were pooled, there was a 
significant association between GFAP expression and age in the STG (p = 0.0029), and 
hippocampus (p = 0.0406) (Figure 3.4).  Using pooled data, there was no association 
between age and GFAP expression in the DLPFC, PVC, or ACC. 
 
3.3.2 Effects of haloperidol treatment on protein expression of glutamine synthetase 
and GFAP in the rat brain 
Most of the patients with schizophrenia in this study were treated with typical 
antipsychotics.  I used Western blot analysis to measure the expression of these astrocytic 
molecules in rats chronically treated (2mg/kg/day) for 28 days with haloperidol.  I did not 
detect differences in protein expression for glutamine synthetase or GFAP in any of the 
brain regions studied (Figure 3.5).   
 
3.4 Discussion 





Figure 3.4 Bivariate plots of GFAP protein expression versus age.  Regression lines 
are shown for diagnosis (schizophrenia and comparison group) plotted separately and 
pooled.  There was a significant interaction for age and GFAP expression when all 
subjects were pooled in the (c) STG (p < 0.001), and (e) hippocampus (p < 0.05), and a 







Figure 3.5 Protein expression of astrocytic molecules were measured in the PFC, 
PVC, STG, ACC, and hippocampus of rats treated chronically treated with 
haloperidol or vehicle.  Expression is shown as mean OD ratio for β-Tubulin with: (a) 
glutamine synthetase and (b) GFAP in the PFC, PVC, STG, ACC, and hippocampus of 
rats treated chronically treated with haloperidol or vehicle.  There were no treatment 
effects detected in any of the brain regions studied. 
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involved with the glutamate cycle and cytoskeletal structure, are abnormally expressed in 
schizophrenia.  Astrocytes are involved in a cycle of synthesis and degradation of 
glutamate.  The enzyme glutamine synthetase contributes to this cycle by converting 
recovered glutamate to glutamine, which is then shuttled back to the presynaptic terminal.  
Thus, altered expression and/or function of this enzyme will have profound effects on the 
glutamate-glutamine cycle and potentially on glutamatergic transmission.  I found 
decreased protein expression of this enzyme in the ACC and STG in schizophrenia, 
suggesting a decreased capacity to cycle glutamate in these regions.   
The cytoskeletal integrity of astrocytes is vital for normal brain functioning.   
Changes in GFAP expression leading to abnormal structure and function of astrocytes, 
including decreased process branching, have been linked to impairments in synaptic 
functioning and abnormal behavior.  I found decreased GFAP protein in the ACC in 
schizophrenia, suggesting that astrocyte-mediated brain functions are impaired in 
schizophrenia.  
 
3.4.1 Expression of glutamine synthetase in schizophrenia 
There are few studies of glutamine synthetase expression in schizophrenia.  
However, my results are consistent with a study that demonstrated deceased protein 
expression in area 10 of the PFC in schizophrenia (Burbaeva et al., 2003).  Consistent 
with reports of multiple isoforms of glutamine synthetase (Chakrabarti et al., 1995; 
Boksha et al., 2000), the study by Burbaeva et al. showed that protein expression of an 
enzyme similar in activity and immunoreactivity to glutamine synthetase, termed 
glutamine synthetase like protein (GSLP), was increased in this brain region.  In addition 
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to protein levels, this study measured the transferase activity of glutamine synthetase and 
GSLP; however, no changes were detected.  Taken together, unchanged enzyme activity 
and expression changes in the opposite direction suggest that glutamine synthetase and 
GSLP may be differentially regulated in disease states by astrocytes.  Furthermore, these 
data suggest that the study of glutamine synthetase may be confounded by the presence of 
multiple distinct isoforms and that past reports of unchanged glutamine synthetase 
activity may have been due to a summation of activity from multiple isoforms  (Gluck et 
al., 2002). 
The activity of glutamine synthetase is, in part, controlled by NMDA receptor 
activation (Watts et al., 2005).  Following presynaptic glutamate release and subsequent 
receptor activation neurons release nitric oxide (NO), a key biological messenger and 
neurotransmitter, which diffuses to bordering astrocytes and decreases glutamine 
synthetase activity (Kosenko et al., 2003).  Conversely, decreased NMDA receptor 
activation lessens inhibition of glutamine synthetase.  Abnormalities of NMDA receptor 
expression, assembly, cellular localization, and binding have been shown in the ACC and 
STG in schizophrenia (Humphries et al., 1996; Grimwood et al., 1999; Corre et al., 2000; 
Kristiansen et al., 2006), so it is possible that illness-related changes in NMDA receptor 
activation could keep glutamine synthetase in a chronically active state.  In turn, this 
could signal astrocytes to decrease production of glutamine synthetase or to increase 
protein disassembly and degradation to correct for abnormally high activity (Kosenko et 
al., 2003). 
Abnormal glutamine synthetase expression in the ACC and STG may be due to 
other brain regions implicated in glutamatergic dysfunction, such as the thalamus.  The 
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thalamus is a relay station of multiple sensory inputs that processes information from 
multiple cortical regions.  Some of the sensory and cognitive disturbances seen in 
schizophrenia are consistent with glutamatergic dysfunction of thalamic circuitry (Gao et 
al., 2000; Ibrahim et al., 2000; Smith et al., 2001a; Smith et al., 2001b; Clinton et al., 
2006; Huerta et al., 2006).  Transcript expression studies of glutamatergic molecules in 
the thalamus by our laboratory have revealed many changes in this illness: increased 
vesicular glutamate transporters, decreased NMDA receptor subunits and proteins 
involved in receptor trafficking, increased astrocytic EAAT1 and 2 and increased EAAT 
interacting proteins (for review Clinton et al., 2003; Clinton and Meador-Woodruff, 
2004).  Our laboratory has also demonstrated that glutamine synthetase transcript levels 
in the thalamus are increased in several nuclei, including those that project to the ACC 
and STG (Bruneau et al., 2005).  Increased transcript expression of thalamic glutamine 
synthetase may be a compensatory response to decreased glutamine synthetase protein or 
to abnormal assembly leading to decreased enzyme activity.  Reduced glutamate 
recycling in the thalamus could cause abnormal glutamatergic transmission and 
potentially affect astrocyte gene expression in areas that receive thalamic efferent 
projections, such as the ACC and STG.    
Alternatively, decreased glutamine synthetase expression, especially in areas 
exhibiting decreases in GFAP, may reflect region-specific loss of astrocytes.  I suggest 
that my findings of decreased glutamine synthetase protein in the ACC and STG may be 
related to: 1) abnormal enzyme activity, 2) glutamatergic dysfunction spanning several 
brain regions, and/or 3) loss of astrocyte density.   
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3.4.2 Expression of GFAP in Schizophrenia 
My data showing decreased expression of GFAP in the ACC are consistent with a 
literature that finds reduced expression of this cytoskeletal protein.  GFAP expression in 
the PFC, as measured by immunohistochemical labeling, has been shown to be 
significantly reduced in schizophrenia (Knable et al., 2001).  Additionally, studies 
demonstrating lamina-specific reductions in the area occupied by GFAP labeled cells 
have been interpreted as evidence of decreased processes branching in this illness 
(Rajkowska et al., 1998; Rajkowska et al., 2002).  Consistent with loss of process 
branching, phosphorylated isoforms of GFAP protein are also decreased, suggesting that 
mechanisms regulating GFAP assembly and disassembly may also be abnormal 
(Johnston-Wilson et al., 2000).  Additionally, immunohistochemical labeling showed a 
reduction in GFAP-positive cells around blood vessels in the DLPFC, suggesting that 
reduced process branching may impede delivery of nutrients to neurons (Webster et al., 
2001).  Taken together, these studies demonstrate that loss of process branching due to 
decreased GFAP expression may be contributing to astrocytic dysfunction, effectively 
causing wide-spread dysfunction in schizophrenia. 
In a previous study examining a similar subject cohort, I reported decreased 
transcript expression in the DLPFC; however, in the present study I did not find protein 
changes in this region.  Conversely, I previously demonstrated increased transcript 
expression of GFAP in the ACC, and now report reduced expression in this region.  
These data suggest that regulation of transcript and protein expression is region-specific.  
Furthermore, these findings suggest that astrocytes in some brain regions, such as the 
ACC, may exhibit a compensatory upregulation of transcript because of decreased 
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protein expression.   
Several studies have demonstrated that GFAP mRNA and protein increase with 
age without an accompanying change in astrocyte density (Hansen et al., 1987; Nichols et 
al., 1993; Kohama et al., 1995; David et al., 1997).  Consistent with these findings, my 
analysis of pooled data, which included both diagnostic groups, showed that GFAP 
expression increased with age in all of the brain regions studied (Fig. 3.4).  There was a 
positive correlation between GFAP expression and age that reached statistical 
significance in the STG (r = 0.443, p = 0.003) and hippocampus (r = 0.329, p = 0.041), 
and was marginally significant in the ACC (r = 0.285, p = 0.058).  However, when 
subjects were analyzed separately by diagnosis group none of the measures reached 
statistical significance (Fig. 3.4).   
My findings in the ACC demonstrate that decreased GFAP in schizophrenia may 
be evidence of: 1) a potential loss of process branching, 2) region-specific compensatory 
gene regulation and, 3) illness-related expression changes inconsistent with predicted 
changes caused by aging.  It is worth mentioning the possibility that a population of 
astrocytes with decreased GFAP expression, and therefore, loss of process branching, 
could contribute to reduced glutamine synthetase expression by limiting the reuptake of 
synaptic glutamate.  In turn, this could result in a decreased capacity to cycle glutamate 
causing wide-spread dysfunction.   
 
3.4.3 Effects of Haloperidol on expression of glutamine synthetase and GFAP in the rat 
brain  
The majority of the subjects with schizophrenia were treated with typical 
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antipsychotics, which could potentially affect the expression of glutamine synthetase 
and/or GFAP.  I investigated the protein expression of these molecules in rats chronically 
administered haloperidol using a schedule of 1 mg/kg/day for 28 days (Spurney et al., 
1999; Halim et al., 2004; Schmitt et al., 2004).  I did not find any changes in glutamine 
synthetase expression in any of the brain regions of the treated rats, suggesting that my 
findings of decreased glutamine synthetase protein are not due to a medication effect.   
There are few reports describing the effects antipsychotic treatment on the 
expression of glutamine synthetase.  Studies measuring brain glutamine synthetase 
protein levels do not find changes that can be related to antipsychotic treatment 
(Burbaeva et al., 2003; Toro et al., 2006).  However, recently it was reported that 
peripheral protein levels of GSLP, an isoform of glutamine synthetase, may be altered by 
treatment with antipsychotics.  Burbaeva et al. demonstrated that increased platelet 
expression of GSLP in schizophrenia is reduced following treatment with the atypical 
antipsychotic, olanzapine (Burbaeva et al., 2006).  The activity of this enzyme may also 
be under the influence of antipsychotic medication.  A study found that glutamine 
synthetase activity was increased in various regions of the rat brain after a single dose of 
the typical antipsychotic chlorpromazine, and was increased in the cerebral cortex after 
long-term administration (Chandrakala et al., 1987).   
I did not find changes in GFAP expression in rats treated with haloperidol either.  
This is consistent with a recent study that failed to detect changes in the GFAP protein 
expression in rat frontal cortex following chronically administered haloperidol (Dean et 
al., 2006).  The literature surrounding acute and chronic treatment with haloperidol does 
not resolve whether changes to astrocyte density or to the expression of astrocytic 
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molecules such as GFAP can be attributed to antipsychotics.  Reportedly, rats given a 
single dose of haloperidol did not demonstrate astrocyte activation as measured by double 
immunofluorescence labeling of c-fos and GFAP (Ma et al., 2003).  Another study 
reported that MK801-induced astrocyte density and GFAP immunoreactivity increases in 
the rat cingulate and retrosplenial cortices can be prevented by the atypical  antipsychotic 
clozapine, but not by haloperidol (Arif et al., 2007).  It remains uncertain whether 
haloperidol influences glutamine synthetase or GFAP expression, and whether any one 
animal model parallels this treatment in humans.   
In this study, I report decreased glutamine synthetase in ACC and STG in 
schizophrenia, and decreased GFAP protein in the ACC.  Further study is needed to 
clarify whether these changes are associated with altered cell density, altered process 
branching, or with compensatory mechanisms secondary to this illness.  My data support 
the hypothesis that astrocytes contribute to the pathophysiology of schizophrenia, and 
that astrocytic molecules involved in glutamatergic function and cytoskeletal integrity are 




SERINE RACEMASE PROTEIN EXPRESSION IN THE CORTEX AND 
HIPPOCAMPUS IN SCHIZOPHRENIA                                                              
 
4.1 Introduction 
As discussed in previous chapters, glutamate neurotransmission has been 
hypothesized to be abnormal in schizophrenia.  This is based in part on pharmacological 
data indicating that antagonists of the NMDA receptor, such as PCP, can induce 
schizophreniform symptoms in non-psychiatrically ill individuals, and exacerbate these 
symptoms in patients with schizophrenia (Javitt, 1987).  Our laboratory has reported 
changes in the expression of numerous molecules associated with the transport, reuptake 
and recycling of glutamate in schizophrenia, including multiple studies demonstrating 
altered expression of NMDA receptor, subunits and binding sites, as well as associated 
postsynaptic density proteins that facilitate intracellular signaling (McCullumsmith and 
Meador-Woodruff, 2002; Clinton and Meador-Woodruff, 2004; Mueller and Meador-
Woodruff, 2004; Bruneau et al., 2005; Kristiansen and Meador-Woodruff, 2005).  
The vast majority of reported schizophrenia-associated abnormalities are of 
neuronal molecules.  Astrocytes, a specialized type of glial cell, are also present at the 
excitatory synapse and are intimately involved with glutamatergic transmission and 
NMDA receptor function.  In particular, the synthesis of the NMDA receptor co-agonist 
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D-serine is via serine racemase, a PLP-dependent enzyme expressed 
predominantly in astrocytes that co-localize to areas of the brain replete with NMDA 
receptors (Schell et al., 1995; Wolosker et al., 1999a; Miranda et al., 2000).  Serine 
racemase has been proposed as the main regulator of both intra- and extracellular D-
serine concentrations in the forebrain by conversion of L-serine to D-serine following 
glutamate-induced activation of kainate and α-amino-3-hydroxy-5-methyl-4-isoxazole 
propionic acid (AMPA) receptors, and by an α, β-elimination reaction, respectively (Kim 
et al., 2005; Strisovsky et al., 2005). 
Co-localization of serine racemase and D-serine-containing astrocytes with the 
NMDA receptor complex suggests a functional relationship (Schell et al., 1995).  D-
serine binds with a high affinity to the modulatory strychnine-insensitive glycine site on 
the NMDA receptor NR1 subunit; thus, D-serine producing astrocytes directly modulate 
NMDA receptor activity (Hashimoto et al., 1993; Matsui et al., 1995; Mothet et al., 
2000).   
Recent studies have reported decreased levels of D-serine in the serum and CSF 
of patients with schizophrenia (Hashimoto et al., 2003; Hashimoto et al., 2005).  
Additionally, patients with schizophrenia who received D-serine along with antipsychotic 
treatment showed improvement in both positive and negative symptoms, as well as in 
cognition (Tsai et al., 1998; Heresco-Levy et al., 2005).  Over-expression of D-amino 
acid oxidase, the enzyme responsible for catabolizing D-serine, reduces NMDA receptor 
activity (Mothet et al., 2000).  Genetic evidence suggests linkage in a subset of patients 
with schizophrenia for polymorphisms in functionally related genes that encode and 
regulate D-amino acid oxidase (Chumakov et al., 2002).   
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Serine racemase has not yet been studied in the brain in schizophrenia, although 
the distribution of NMDA receptors and serine racemase-expressing astrocytes in the 
hippocampus, cortex and other cerebral structures coincides with areas of glutamatergic 
dysfunction in this illness (Goff and Coyle, 2001a; Harrison et al., 2003).  I hypothesize 
that there are alterations of serine racemase expression in schizophrenia in brain regions 
that have in the past demonstrated NMDA receptor abnormalities.  Accordingly, I 
measured protein expression of serine racemase using Western blot analysis in elderly 
subjects with schizophrenia and a non-psychiatrically ill comparison group in the 
DLPFC, ACC, STG, and hippocampus.  Additionally, I studied the PVC, an area not as 
closely implicated in glutamatergic abnormalities in schizophrenia, to determine 
specificity of findings.   
 
4.2 Methods 
4.2.1 Acquisition and processing of human brain tissue.   
Fifty subjects from the Mount Sinai Medical Center and Bronx Veterans 
Administration Medical Center were used for this study, consisting of 27 non-
psychiatrically ill individuals and 23 patients with schizophrenia.  Subjects were 
diagnosed with schizophrenia if the following criteria were fulfilled: 1) the presence of 
schizophrenic symptoms could be documented before age 40; 2) the medical records 
contained evidence of psychotic symptoms and at least 10 years of psychiatric 
hospitalization with a diagnosis of schizophrenia; 3) a DSM-III-R diagnosis of 
schizophrenia was agreed upon by two experienced clinicians; 4) neuropathologic 
examination did not reveal Alzheimer’s disease or other discernable neuropathologic  
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Table 4.1 Subject characteristics for Mount Sinai and Bronx Veterans Administration 
Medical Centers cohort – serine racemase study  
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abnormalities.  A summary of subject characteristics is shown in Table 4.1.   
Brains obtained at autopsy were divided mid-sagittally at the time of extraction.  The 
right half was fixed in 4% formaldehyde and used for neuropathological characterization.  
The left half was sectioned in 6-8 mm coronal slabs, immediately snap-frozen, and stored 
at –80oC.  The areas of interest were dissected from the frozen slabs (Dracheva et al., 
2005).  Dissected never-thawed tissues were pulverized at –190oC into a fine powder and 
aliquoted into individual Eppendorf tubes and stored at –80oC.   
 
4.2.2 Acquisition and processing of rodent brain tissue.   
Twenty-two adult, male Sprague-Dawley rats (250g) were housed two-three to a 
cage, with food and water ad libitum.  Animals were treated with daily intramuscular 
injections of haloperidol dissolved in dimethyl sulfoxide (DMSO) (Fisher Scientific, Fair 
Lawn, NJ, USA) (1 mg/kg/day, n=11), or vehicle (DMSO) (n=11) for 29 days.  Twenty-
four hours after the last injection, the animals were sacrificed and brains were 
immediately removed, dissected, and frozen in isopentane.  The frontal, cingulate, 
occipital, and temporal cortices, and hippocampus were dissected according to The Rat 
Brain in Stereotaxic Coordinates (Paxinos and Watson, 1986).  The brains were stored at 
−80°C until assayed.  All animal experiments were approved by the University 
Committee on the Use and Care of Animals at the University of Michigan and were 
performed according to the guidelines for The Care and Use of Laboratory Animals of 




4.2.3 Tissue preparation.   
Tissue specimens (human 50mg, rodent 20mg) were homogenized in 1ml of 5mM 
Tris–HCl (pH 7.4), containing Complete, mini, EDTA-free protease inhibitor cocktail 
tablets (Roche Applied Science, Indianapolis, IN) (1 tablet/10mls) for 30 seconds with a 
PowerGen 125 homogenizer (Fisher Scientific).  Total protein concentration was 
determined with a BCA Protein Assay Kit (Pierce) and fluorescence was measured on a 
SpectraCount absorbance microplate reader (Packard) at 540 nm.  Homogenates were 
stored at -80oC until assay.   
 
4.2.4 Western blot analysis.   
Samples were prepared by combining tissue homogenate with sample buffer 
(62.5mM Tris-HCl, 20% glycerol, 2% sodium dodecyl sulfate, 5% β-mercaptoethanol, 
pH 6.8) and heated at 95o C for four minutes.  Samples were loaded onto pre-cast 10% 
polyacrylamide Tris-HCl gels (Bio-Rad) in duplicate (20µg protein/well) and run in 
SDS/Tris/glycine buffer (25mM Tris-HCl, 192mM glycine, 0.1% SDS, pH 8.3) at 130 
mV for about one hour.  Following transblotting to nitrocellulose membranes in Tris-
glycine buffer (25mM Tris, 192mM glycine, pH 8.3), blots were blocked with 1% 
powdered milk in PBS (pH 7.4), and agitated for two hours at room temperature and then 
overnight at 4oC with a monoclonal antibody directed against mouse serine racemase (BD 
Biosciences, San Diego, CA) at a dilution of 1:500 in 1% powdered milk in PBS.  Next, 
blots were washed in PBS and incubated with a horseradish peroxidase-coupled goat anti-
mouse secondary antibody (Santa Cruz Biotechnology, INC.) for three hours on a shaker 
at room temperature.  Following four washes in PBS and two washes in distilled water, 
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enhanced chemiluminescence (ECL) was used for detection.  Blots were saturated with 
ECL reagent (Amersham, Piscataway, NJ), covered in plastic wrap and exposed to ECL 
film (Amersham, Piscataway, NJ).  Film was developed and digitally captured with a 
CCD based imaging system using Scion Imaging software 4.0.3.  Gray scale values were 
obtained for protein bands at the expected molecular weight (38kDa), membrane 
background was subtracted, and the adjusted gray scale values from duplicate samples in 
adjacent lanes were averaged and converted to optical density.   Membranes were 
stripped and re-blotted for β-Tubulin (Upstate, lake Placid, NY), as a loading control, and 
the mean ratio of serine racemase /β-Tubulin optical density was used for data analysis. 
 
4.2.5 Statistical analysis.  
Statistical analysis was performed with Statistica (StatSoft, Tulsa, OK).  
Correlation analysis was performed to investigate possible associations between protein 
expression and age, postmortem interval, and tissue pH.  I analyzed data from each 
region by one-way ANOVA, with diagnosis as the independent variable and mean optical 




4.3.1 Protein expression of serine racemase in schizophrenia 
I used Western blot analysis to measure the expression of serine racemase in the 
brain in schizophrenia.  Serine racemase was detected in all five of the brain regions 
studied, with a band at the expected molecular weight of 38kDa.  Correlation analysis 
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showed no associations between serine racemase expression and age, postmortem 
interval, or pH in any of the areas examined.  I found a main effect for diagnosis for 
increased serine racemase expression in the hippocampus in schizophrenia (F(1, 44) = 
5.199; p = 0.028) (Figure 4.1a).  There was no effect of diagnosis on serine racemase 
expression in any of the cortical areas studied (Figure 4.1b-e).   
 
4.3.2 Effects of haloperidol treatment on protein expression of serine racemase in the 
rat brain 
Most of the patients with schizophrenia in this study were treated with typical 
antipsychotics.  I used Western blot analysis to measure the expression of serine 
racemase in rats chronically treated (2mg/kg/day) for 28 days with haloperidol.  There 
was a significant effect for treatment in the PVC (F(1, 19) = 7.52; p = 0.013).  Treatment 
with haloperidol decreased serine racemase expression in the PVC of the rat brain.  I did 
not detect differences in protein expression for serine racemase in any of the other brain 
regions studied (Figure 4.2).   
 
4.4 Discussion 
Linking astrocytic function to schizophrenia represents a divergence from work 
that has historically focused on changes primarily attributable to neurons.  Based on the 
coordinated activity of neuronal and astrocytic molecules in glutamatergic transmission 
and NMDA receptor function, I used human postmortem tissue to study brain regions 
implicated as areas of glutamatergic dysfunction in schizophrenia: the hippocampus and 





Figure 4.1 Serine racemase protein expression in the hippocampus, DLPFC, ACC, 
STG, PVC in schizophrenia. Expression is shown as mean OD ratio for β-Tubulin with 
serine racemase.  (a) Serine racemase protein expression is increased in the hippocampus 






Figure 4.2 Protein expression of serine racemase in the PFC, PVC, STG, ACC, and 
hippocampus of rats chronically treated with haloperidol or vehicle.  There was a 
significant effect for treatment in the PVC (F(1, 19) = 7.52; p = 0.013).  Treatment with 
haloperidol decreased serine racemase expression in the PVC of the rat brain.  There 
were no treatment effects detected in any of the other regions studied. 
 
 102 
significant increase in the expression of serine racemase protein in the hippocampus in 
schizophrenia.   
The hippocampus plays an important role in learning and in verbal and spatial 
memory via its connections with virtually all association cortices.  Additionally, it plays a 
role in long term potentiation, a component of memory specifically linked to NMDA 
receptor activity.  Diminished cognitive processing, often a feature of schizophrenia, and 
evidence for structural and functional hippocampal pathology, have implicated the 
hippocampus, which is a brain region of particular sensitivity to insult in this illness 
(Harrison, 2004).   
NMDA receptor antagonists such as (+)-5-methyl-10, 11-dihydro-5H-dibenzo [a, 
d] cyclohepten-5, 10-imine (MK-801) and PCP, have been shown to alter various 
components of the glutamatergic neurotransmitter system, including those associated 
with astrocytes.  These results include evidence that NMDA receptor function influences 
the transcript expression of serine racemase in the hippocampus and other brain areas 
(Yoshikawa et al., 2004).  Whether changes in the expression of serine racemase are the 
result of neuronal or astrocytic NMDA receptor blockade, or both, my data demonstrate 
alterations of an astrocyte-derived rapid response system that is sensitive to changes 
potentially affecting multiple components of the glutamatergic synapse.  It should be 
noted that although there are no direct linkages to serine racemase reported, an 
association may exist upstream of serine racemase for a regulatory gene in a pathway that 
modulates the expression and/or activity of this enzyme. 
Several studies have identified abnormal expression of glutamatergic molecules in 
schizophrenia.  The present findings provide evidence for an astrocytic component to 
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these abnormalities which should be replicated in other relevant schizophrenia cohorts.  
Furthermore, this study indicates that brain expression of the neuromodulator D-serine 






5.1 Summary of findings 
Numerous studies demonstrate the major supportive roles that astrocytes and 
astrocyte-related molecules play in brain function, including contributions to energy 
metabolism, regulation of ion concentrations, intracellular signaling, and glutamatergic 
neurotransmission.  Four astrocytic molecules, in particular - GFAP, S100β, glutamine 
synthetase, and serine racemase - have emerged as being especially important for serving 
these functions (Figure 5.1).  Therefore, a breakdown in the structure or function of these 
molecules could have profound effects on brain function.  While GFAP is a major 
component of the astrocytic cytoskeleton, only a small portion of its functions are known.  
GFAP has been shown to regulate process extension, enabling astrocytes to monitor and 
respond to changes in the environment (Weinstein et al., 1991; Chen and Liem, 1994), 
and its expression may have a reciprocal relationship with glutamatergic transmission 
(Porter and McCarthy, 1995; Kommers et al., 2002; Hu et al., 2003).  I found that GFAP 
transcript expression was decreased in the DLPFC and increased in the ACC in 
schizophrenia, and that GFAP protein expression was decreased in the ACC in 
schizophrenia.  S100β, a signaling molecule with a multitude of functions, modulates 





Figure 5.1 Summary of results.  The transcript and protein expression of the astrocytic 
molecules GFAP, S100β, glutamine synthetase, and serine racemase were measured in 
schizophrenia.  GFAP transcript expression was decreased in the DLPFC and increased 
in the ACC, and GFAP protein expression was decreased in the ACC.  Glutamine 
synthetase protein was decreased in the STG and ACC.  Serine racemase protein was 
increased in the hippocampus in schizophrenia. 
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detect any changes in S100β transcript expression in schizophrenia.  The astrocytic 
enzyme glutamine synthetase maintains the tightly regulated glutamate-glutamine cycle, 
which in turn controls levels of metabolic substrates, neurotransmitter levels, and also 
protects cells from excitotoxicity.  I found decreased protein expression of glutamine 
synthetase in the STG and ACC in schizophrenia; however, I did not detect any changes 
to glutamine synthetase transcript expression in the ACC.  Finally, serine racemase is the 
enzyme responsible for synthesizing D-serine, an NMDA receptor co-agonist that 
facilitates glutamatergic signaling, learning and memory-mediated LTP.  My findings 
show that serine racemase protein levels are increased in the hippocampus in 
schizophrenia. 
 
5.2 Altered expression of astrocyte-related molecules in schizophrenia: global 
astrocytic lesion or discrete regional and molecular defects   
The study of potential astrocytic abnormalities in schizophrenia represents a 
relatively new line of investigation, as the majority of work to date has focused on 
neuronal dysfunction in this illness.  One of the preliminary findings that suggested a role 
for astrocytes in schizophrenia was altered cell density in several brain regions thought to 
be involved in the pathophysiology of the illness.  Thus, it was hypothesized that a loss of 
astrocytes, or compromised astrocytic functioning in those particular brain regions, could 
contribute to brain dysfunction in schizophrenia.  Although, subsequent research has 
failed to show prominent changes in astrocyte density in select brain regions in 
schizophrenia, an alternate hypothesis suggests that a global astrocytic lesion may give 
rise to brain abnormalities observed in the illness.  Specifically, this theory posits that 
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widespread expression changes in structural and functional astrocytic molecules may 
contribute to prominent dysfunction of neural circuits in the brains of patients with 
schizophrenia.  Thus, the current body of work sought to determine whether the 
expression of four major astrocytic molecules – GFAP, S100β, glutamine synthetase, and 
serine racemase was collectively altered across multiple brain regions in schizophrenia.  
 
5.2.1 Regional transcript and protein expression changes in the brain in schizophrenia. 
Within these studies, no individual brain region emerged as being a focal point of 
acute altered astrocytic marker expression; instead, several regional expression deficits 
were found.  I identified three brain regions, the DLPFC, STG, and hippocampus, which 
showed altered expression of astrocytic markers; however, each area exhibited altered 
expression for just one out of the four molecules measured.  Each region had been 
previously implicated in schizophrenia, with evidence of structural and/or functional 
deficits.  Based on data for the four molecules that I studied, astrocytic contribution to 
brain dysfunction in these areas is discrete.  The ACC appeared to be the most affected 
region, with two different molecules (GFAP and glutamine synthetase) showing altered 
expression.  The literature regards the ACC as an area having structural, functional, and 
gene expression changes in schizophrenia, and my data suggest that astrocytic 
abnormalities may play a role in ACC dysfunction.  In contrast to the other four regions 
studied, I did not find altered transcript or protein expression for any of the molecules 
studied in the PVC.  This was not entirely unexpected; as mentioned previously this area 
has often been used as a “control region” to compare with other commonly affected 
areas.  My data do not support comprehensive dysfunction of astrocytes in schizophrenia; 
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rather, these results suggest that changes in the expression of astrocytic molecules are 
localized to specific areas.   
 
5.2.2 Direction of transcript and protein expression change of astrocytic molecules in 
schizophrenia. 
There were no consistent patterns in the direction of change for transcript or 
protein expression for any of the molecules studied.  A predominance of decreased 
expression of astrocytic molecules, both transcript and protein, could suggest a net loss of 
astrocytes overall, or loss of a specific subset of astrocytes that expressed particular 
molecular markers.  Meanwhile, an overall increase in expression might suggest a wide-
spread compensatory upregulation, a faulty feedback mechanism chronically signaling 
for increased expression, or support gliosis and an increase in astrocytes.  Instead of any 
uniform changes, I observed opposite patterns of GFAP transcription changes in the 
DLPFC versus ACC.  Despite reports of altered protein expression of GFAP in 
schizophrenia, there is little information regarding transcript expression in the literature 
with which to compare and interpret these results.  GFAP mRNA levels were decreased 
in the DLPFC in schizophrenia, which may suggest that events that modulate gene 
transcription, such as astrocyte activation, are abnormal in schizophrenia.  I did not detect 
changes in GFAP protein expression in this region, however, which may indicate a 
compensatory mechanism where astrocytes decrease GFAP protein turnover by inhibiting 
phosphorylation-mediated disassembly of this cytoskeletal protein.   
In contrast to findings in the DLPFC, GFAP transcript expression was 
significantly increased in the ACC.  This is a divergence from protein expression findings 
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that predominantly show decreases in GFAP (Johnston-Wilson et al., 2000; Cotter et al., 
2001; Knable et al., 2001; Webster et al., 2001a).  Increased GFAP transcript expression 
in the ACC may be due to altered gene splicing during transcription, either by the 
improper removal of exons or by introns that remain unspliced, either of which could 
result in an unstable and short-lived protein product.  Alterations in the rates of synthesis 
and breakdown of astrocytic proteins has been hypothesized to exist in schizophrenia 
(Burbaeva et al., 2007), and would offer an interesting explanation for the discrepant 
transcript and protein data.  My findings of increased transcript expression of GFAP in 
the ACC may reflect a compensatory upregulation in response to increased recycling of 
protein.   
I also found altered protein levels of two other molecules, glutamine synthetase 
(in the ACC and STG) and serine racemase (in the hippocampus).  These expression 
changes were not uniform in direction either.  Glutamine synthetase protein expression 
was decreased in the ACC and STG in schizophrenia, whereas serine racemase protein 
levels were increased in the hippocampus.  By virtue of their heterogeneous nature, these 
results argue that transcript and protein expression are not altered in a manner suggestive 
of a global astrocytic lesion, but rather, changes are discrete and molecule-specific.   
 
5.3 The expression of astrocytic structural and functional molecules is altered in 
schizophrenia: analysis by molecule 
5.3.1 Analysis by molecule: S100β 
All of the molecules studied showed some level of expression change, either 
transcript, protein, or both, except for S100β.  This finding was unexpected given a 
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literature depicting S100β alterations in CSF and serum of patients with schizophrenia.  
However, since I only measured S100β transcript expression, I cannot exclude the 
possibility of protein expression changes.  There is only one other study reporting brain 
expression of S100β, and it showed that S100β protein expression was unchanged in the 
DLPFC in schizophrenia (Dean et al., 2006).  Whether or not these results are of 
particular relevance to the present findings is unclear, but there is support for consistency 
across studies by the fact that they, too, did not detect GFAP protein expression changes 
in the DLPFC.   
Altered CSF and serum S100β levels in patients with schizophrenia have been 
interpreted as a sign of either increased astrocyte activation or of cells leaking contents 
into peripheral fluids.  However, the notion of leaking cells is not supported by a recent 
study which showed that patients with schizophrenia did not exhibit increased levels of 
GFAP or myelin basic protein along with increased levels of S100β in serum and CSF 
(Steiner et al., 2006).  Other work showing that S100β serum levels increased 
simultaneously with levels of myo-inositol, a product of the phosphatidylinositol second 
messenger system, in patients with schizophrenia suggests that increased S100β may 
instead correlate with astrocyte activation (Malhi et al., 2002).  Thus, the scarcity of 
reports on S100β brain expression makes CSF and serum level data difficult to interpret.  
More studies integrating these measures are needed to clarify the pathophysiological 
significance of these findings. 
 
5.3.2 Analysis by molecule: GFAP 
Earlier reports speculated that altered GFAP transcript expression may result in an 
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unstable and short-lived protein.  Protein function of this molecule is mediated by the 
phosphorylation of several sites on the N-terminal head of the protein, and a site localized 
to the tail end of the filament.  During GFAP transcription, incorrect splicing patterns 
could result in the loss of function mediated by phosphorylation.   
Within the astrocyte, GFAP undergoes assembly and disassembly in accordance 
with the needs and functional states of the cell.  Phosphorylated GFAP exists as 
unassembled subunits in a soluble pool that are interchangeable with polymerized 
counterparts.  Normally, equilibrium of phosphorylated soluble GFAP is maintained with 
GFAP within the cytoskeleton (Takemura et al., 2002).  The phosphorylation of GFAP is 
stimulated by the presence of glutamate and by the absence of Ca2+ (Rodnight et al., 
1997; Kommers et al., 2002).  The mechanisms of glutamate-mediated phosphorylation, 
in part, include synaptic targeting and activation of group II mGluRs expressed by 
astrocytes (Oppelt et al., 2004; Battu et al., 2005).  This activation inhibits the entry of 
Ca2+, possibly through L-type channels, and decreases cytosolic Ca2+, thereby 
downregulating Ca2+-dependent dephosphorylation and increasing polymerization 
(Oppelt et al., 2004).  The phosphorylation state of GFAP also appears to be regulated by 
internal Ca2+, which, like the presence of extracellular Ca2+, causes the dephosphorylation 
of GFAP.    
Phosphorylation takes place via a group of kinases, such as cyclic AMP-
dependent protein kinase (PKA), Ca2+/calmodulin-dependent kinase II, (CaMK II), 
protein kinase C (PKC), and Cdc2 kinase, at various sites, five localized to the N-
terminal head of the protein, and one localized to the tail end of the filament (Rodnight et 
al., 1997).  Phosphorylation results in the disassembly of preformed GFAP and prevents 
 112 
unassembled subunits from incorporating into the astrocytic cytoskeleton (Rodnight et 
al., 1997).  Immunohistochemical and proteomic studies have show that phosphorylated 
isoforms of GFAP are decreased in schizophrenia, suggesting altered function of this 
molecule (Johnston-Wilson et al., 2000; Webster et al., 2001b).   
Alternatively, molecules regulating the expression of GFAP may be abnormal in 
schizophrenia.  Vimentin, another IF protein expressed by astrocytes, has been shown to 
modulate the expression and structure of GFAP filaments (Galou et al., 1996).  In the 
absence of vimentin, GFAP expression is decreased and its incorporation into the 
cytoskeleton is altered. Therefore, a change in GFAP could actually reflect a more wide-
spread abnormality for cytoskeletal proteins in schizophrenia.  There have been few 
studies examining the expression of vimentin in schizophrenia, and so far, none have 
detected any changes (Arnold et al., 1996; Miyamae et al., 1998).   
 
5.3.3 Analysis by molecule: Glutamine synthetase 
The expression and activity of glutamine synthetase, which is hypothesized to be 
a component of glutamatergic dysfunction in schizophrenia (Bruneau et al., 2005; 
Burbaeva et al., 1999; Goff and Coyle, 2001), is influenced by downstream events that 
take place prior to glutamate recycling, for example by molecules regulating the length of 
time glutamate is in the synapse.  This is accomplished by the expression and function of 
EAATs.  Altered EAATs expression has been shown in several brain regions in 
schizophrenia, including the thalamus and cortex (Smith et al., 2001; Matute et al., 2005).  
Although the direction of change for EAAT expression is not consistent, these data, along 
with findings that proteins involved in the trafficking and expression of EAATs are 
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increased in schizophrenia (Bauer, unpublished data), suggest that glutamate reuptake is 
abnormal in schizophrenia.  The release of aracadonic acid, as a result of NMDA receptor 
activity, can affect astrocytic reuptake of glutamate by inhibiting EAAT expression 
(Volterra et al., 1994).  Therefore, it could be hypothesized that NMDA receptor 
hypofunction could abnormally increase EAAT expression.  These factors, in turn, could 
cause downstream changes to the expression and/or activity of glutamine synthetase.   
It is notable that the cycling of glutamate is affected by the expression of GFAP.   
GFAP-null mice are able to transport glutamate normally, but they exhibit increased 
glutamine synthetase activity and levels of glutamine (Pekny et al., 1999).  While I did 
not detect any glutamine synthetase transcript expression changes, I did find decreased 
protein expression in the ACC and STG in schizophrenia.  This finding, along with that 
of decreased GFAP in the ACC in schizophrenia, may indicate abnormal regulation of 
glutamine synthetase under conditions demanding increased glutamate recycling.  
Additionally, I found decreased protein expression of this enzyme in the STG, suggesting 
that a decreased capacity of astrocytes to cycle glutamate may be a common 
manifestation in schizophrenia.  On the other hand, decreased glutamine synthetase 
expression could be a normal response to a system that is exhibiting decreased reuptake 
of synaptic glutamate.  These conditions could result in prolonged activation of synapses, 
which is consistent with evidence for decreased deactivation reported in the ACC and 
STG in schizophrenia (Assaf et al., 2006; Walter et al., 2007). 
 
5.3.4 Analysis by molecule: Serine racemase 
The expression and function of serine racemase in the brain adjusts according to 
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the changing needs of the astrocyte and surrounding neurons (Martineau et al., 2006).  
Therefore, a straightforward interpretation of my finding for increased serine racemase 
protein expression in the hippocampus is that of a compensatory upregulation in response 
to NMDA receptor hypofunction.  Serine racemase expression and activity can directly 
influence neuronal signaling by altering the synthesis of the NMDA receptor co-agonist, 
D-serine.  Conversely, NMDA receptor antagonists such as MK-801 have been shown to 
upregulate serine racemase mRNA expression (Yoshikawa et al., 2004).  The exact 
mechanisms for such activation are not well understood, however.  Evidence from cell 
culture experiments show that activation of AMPA and kainate receptors increases the 
activity of serine racemase and results in the release of D-serine (Schell et al., 1995).  
However, these results have not yet been confirmed in vivo.  In fact, studies in the rat 
striatum showed that treatment with glutamatergic agonists and antagonists did not result 
in D-serine release (Ciriacks and Bowser, 2006).  There is evidence for NMDA receptor-
mediated D-serine release, although it is unclear whether this is due to neuronal or 
astrocytic NMDA receptors (Martineau et al., 2006).   
The hippocampus, because of the high density of NMDA receptors and D-serine 
expression, plays a prominent role in learning, memory, and induction of LTP (Schell et 
al., 1997).  As such, the hippocampus, which exhibits cytoarchitectural abnormalities in 
schizophrenia, including decreased expression of synaptic proteins, may be particularly 
affected by altered NMDA receptor function in this illness (Newell et al., 2007).  
Abnormalities in NMDA receptor function have been definitively linked to D-serine 
levels, which suggests that altered expression and activities of enzymes regulating D-
serine could, in turn, contribute to NMDA receptor hypofunction.  Indeed, associations 
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for genes involved in D-serine metabolism have been linked to schizophrenia.  In 
particular, DAOA, a gene linked to enhanced activity of DAAO, has been shown to 
correlate with decreased activity in the hippocampus during working memory tasks 
(Goldberg et al., 2006).  Increased activity of DAAO, leading to decreased availability of 
synaptic D-serine, may be a predominant component of NMDA receptor hypofunction in 
schizophrenia, and may in turn stimulate the upregulation of hippocampal serine 
racemase expression. 
 A newly published postmortem study has found altered expression of several 
molecules involved in D-serine activity.  They report decreased serine racemase protein 
expression in the hippocampus, and showed that a subset of chronically ill subjects 
exhibited increased protein expression of DAAO (Bendikov et al., 2007).  These findings 
bring up several interesting points.  These data support my findings of altered serine 
racemase expression in the hippocampus in schizophrenia; however, it is notable that the 
two studies report an opposite pattern of expression changes.  This discrepancy could be 
due to an age effect, as my subject cohort was substantially older than the other (mean of 
72 years compared to 39 years).  It is not known whether serine racemase expression or 
activity is effected by aging in humans, but, aged rats show a significant loss of serine 
racemase mRNA and protein expression as well as D-serine levels in the hippocampus, 
accompanied by decreased capacities for learning, memory, and LTP (Mothet et al., 
2006).  Furthermore, neither cognitive deficits nor decreased D-serine levels could be 
attributed to age-related changes in NMDA receptor binding capacity or to altered levels 
of DAAO in these rats, suggesting that serine racemase is directly responsible for these 
hippocampal alterations.  Considering this age-related decrease of serine racemase in rats, 
 116 
one might expect to find decreased serine racemase in the elderly subjects I studied, but 
yet another factor to consider is the effect of illness duration on serine racemase 
expression.  Evidence shows that schizophrenia can initially be characterized by a rapid 
and progressive degeneration of both brain volume and cognitive capacities.  It may be 
the case, then, that younger patients and/or those with shorter illness duration may have 
impairments that change over time as compensatory measures for NMDA receptor 
dysfunction are established.  In support of this theory, studies show that PCP 
administration in rats leads to acute increases of NMDA receptor binding activity, 
however, in the long-term, NMDA receptor binding activity significantly drops, and 
remains low for weeks following drug exposure (Newell et al., 2007).  This interpretation 
may explain the discrepant findings between this work and that of Bendikov et al. in 
these studies; however, it will be interesting to see if it holds true as more reports of 
serine racemase expression in schizophrenia are published. 
It seems unlikely that antipsychotic treatment played a role in either of these two 
reports of serine racemase expression changes, as the majority of subjects in both studies 
were treated with typical antipsychotics, yet showed expression changes in opposite 
directions.  The only explanation then would be that antipsychotics might exert dissimilar 
effects on serine racemase expression according to age and illness duration. 
The issue of serine racemase activity has not been addressed in the protein 
expression studies, but it is an important facet of understanding the role of serine 
racemase in schizophrenia.  The characterization of serine racemase, as well as a 
purported role for this enzyme in schizophrenia, is relatively new.  As such, the 
mechanisms of activity and expression are not yet well understood; although there is 
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evidence to suggest that serine racemase-interacting proteins, such as PICK1 and GRIP, 
participate in the regulation of activity (Kim et al., 2005; Fujii et al., 2006).  An assay 
capable of accurately determining serine racemase activity in human postmortem tissue 
would therefore be of great value.  Details of a proposed experimental design can be 
found in the Future Directions section.  
 
5.4 The expression of serine racemase, glutamine synthetase, and GFAP impact 
excitatory transmission and plasticity in the brain.  
This dissertation work examined astrocytic molecules in five brain regions in 
schizophrenia.  No immediate qualitative pattern emerged that indicated widespread 
abnormalities either across brain regions, or across multiple astrocyte-related molecules, 
thus my findings do not support the idea of a global astrocytic lesion giving rise to the 
pathophysiology of schizophrenia.  The transcript and protein expression of several 
molecules were altered, but the directions of expression changes and the regions in which 
the changes took place varied, so it does not seem that loss of astrocyte density is a 
defining characteristic of schizophrenia, at least in the elderly cohort of patients that were 
examined in these studies.  However, within these results, one major theme does arise--all 
of the astrocytic molecules that demonstrated altered expression in schizophrenia can be 
linked to glutamatergic function.  Furthermore, these results show that altered expression 
of serine racemase, glutamine synthetase, and GFAP individually can reciprocally impact 
the expression and function of the entire group of molecules. 
Glutamatergic dysfunction and specifically hypofunction of the NMDA receptor 
have been demonstrated in schizophrenia (Coyle et al., 2003).  Studies show that under 
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typical conditions the NMDA receptor co-agonist binding site is nearly saturated by D-
serine (Panatier et al., 2006).  However, in response to altered availability of transmitter 
molecules, astrocytes positioned within close proximity of the synapse can alter serine 
racemase expression and activity.  Compensatory upregulation of serine racemase has 
been shown in several brain regions in rats following treatment with the NMDA receptor 
antagonist MK-801, including the hippocampus (Yoshikawa et al., 2004).  Increased D-
serine improves cognitive function in rats with PCP-induced NMDA receptor 
hypofunction (Andersen and Pouzet, 2004), which is consistent with D-serine-mediated 
improvements in patients with schizophrenia (Tsai et al., 1998; Tsai et al., 1999; 
Heresco-Levy et al., 2005).  Thus, my postmortem finding of increased serine racemase 
in schizophrenia is consistent with the notion of compensatory increases in serine 
racemase expression occurring in response to NMDA receptor-mediated glutamatergic 
dysfunction in the hippocampus. 
NMDA receptor hypofunction, through compromised aracadonic acid release, can 
result in decreased glutamate release, which, in turn, may influence the expression of 
astrocytic EAATs.  Such alterations in EAAT expression may lead to decreased 
glutamine synthetase protein expression, since without synaptic signaling and glutamate 
reuptake, glutamine synthetase expression and activity could be down-regulated.  Thus, 
my findings for decreased glutamine synthetase are consistent with the hypothesis of 
NMDA receptor hypofunction in schizophrenia.  But, what about GFAP expression 
changes, how does this molecule fit into an astrocytic model of glutamatergic 
dysfunction?   
The expression of GFAP, like serine racemase and glutamine synthetase, has also 
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been shown to have reciprocal influence with glutamatergic transmission (Porter and 
McCarthy, 1995; Kommers et al., 2002; Hu et al., 2003).  Astrocytic processes are 
closely associated with glutamatergic synapses where they have a direct role in NMDA 
receptor activation via the synthesis and release of gliotransmitters such as D-serine and 
in the reuptake and cycling of synaptic glutamate via EAATs and glutamine synthetase 
(Figure 5.2).  The ability of astrocytes to change process morphology in response to 
changing synaptic conditions is mediated by GFAP expression.  Therefore, my findings 
of decreased GFAP expression in schizophrenia may signify that altered process 
morphology contributes to glutamatergic dysfunction in this illness.  Alternatively, it may 
demonstrate a compensatory response by astrocytes to abnormal glutamatergic 
transmission.   
A dramatic example of GFAP expression changes altering glutamatergic 
transmission can found in the supraoptic nucleus (SON) of the hypothalamus.  This 
region is interspersed with neurons that synthesize and release oxytocin and vasopressin, 
two neuroendocrine molecules associated with events following parturition, such as 
lactation, and with maintaining water balance, respectively.  It is an area also highly 
populated by astrocytes that cover an estimated 99% of neuronal synapses with their 
processes during basal conditions (Hatton, 1997).  However, under certain conditions 
astrocytes in the SON undergo an interesting transformation.  At the onset of lactation in 
the rat, astrocytic processes that normally ensheath synapses exhibit a decrease in the 
expression of GFAP and begin to physically retract away from the synapse.  As processes 
are pulled away several changes mediating enhanced synaptic functioning occur.  First, in 





Figure 5.2 Astrocytic processes are closely associated with glutamatergic synapses. 
Astrocytes play a direct role in NMDA receptor activation via the synthesis and release of 
gliotransmitters such as D-serine, by the reuptake of synaptic glutamate by EAATs and 
the cycling of glutamate by glutamine synthetase.  NMDA receptors are typically located 
within the synapse and are activated by presynaptic glutamate release.  Glutamate release 
activates postsynaptic AMPARs causing membrane depolarization via Na+ influx.  This, 
along with the binding of glutamate and D-serine, results in the removal of Mg+ from the 
receptor channel and allows influx of Ca2+.  Upon activation, these receptors set into 
motion a series of events, including increased AMPA receptor trafficking and CREB and 
protein kinase activation leading to gene transcription.  If a series of these depolarizations 
or excitatory post synaptic potentials (EPSPs) occur it leads to LTP.    
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Second, both the concentration and the period of available synaptic glutamate increase in 
the absence of EAAT-bearing astrocytic processes (Piet et al., 2004) (Figure 5.3).  Third, 
physical barriers around the synapse once created by astrocytes are removed allowing 
neurons to make otherwise unattainable contacts.  What follows is an increase in the 
clustering and chemical coupling of neurons and an increase in the formation of new 
synapses (Hatton, 1997).  Additionally, the removal of astrocytic processes permits 
signaling to occur over larger distances through the spillover of extrasynaptic glutamate.  
The end result is an “inter-synaptic crosstalk” between neurons that creates a temporally 
and spatially synchronized signal.  In the lactating rat, these actions shift cells out of a 
slow basal level of irregular neuronal firing to a strong and rhythmic synaptic response 
that result in the release of oxytocin and milk letdown.  Mechanistically, the retraction of 
processes allows extrasynaptic glutamate to begin a tonic activation of presynaptic 
mGluRs (Oliet et al., 2001; Piet et al., 2004).  Studies indicate that this activation results 
in decreased spontaneous release of presynaptic glutamate that in turn inhibits 
GABAergic synapses (Piet et al., 2004).  This silencing of GABAergic synapses, along 
with increased neuron excitability mediated by increased extracellular [K+] and increased 
synaptic clustering, augments regional excitability.  Thus, by altering process 
morphology during lactation astrocytes regulate glutamatergic transmission.  The 
presence of astrocytic processes can also alter the amount of stimulation needed to induce 
synaptic plasticity (LTP versus LTD), thereby changing the potentiation of individual 
synapses (Panatier et al., 2006). 
These are remarkable roles for GFAP in excitatory transmission and synaptic 





Figure 5.3 The retraction of astrocyte processes enables inter-synaptic crosstalk. The 
removal of astrocytic processes allows synaptic glutamate to activate distant synapses 
which are otherwise prevented by the physical presence of astrocytes and by astrocyte-
mediated glutamate reuptake via EAATs. 
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from the lactating rat to psychiatric illness.  To create a workable model in which 
astrocyte process retraction, mediated by GFAP expression changes, contributes to 
glutamatergic dysfunction in schizophrenia, some basic criteria should be discussed.  
Evidence should show that astrocyte-mediated changes to excitatory transmission 
mediated by GFAP expression: (1) occurs in circumstances other than lactation, (2) 
involves molecules implicated in glutamatergic dysfunction in schizophrenia, and (3) 
accounts for abnormal brain function reported in schizophrenia.  If these criteria are met, 
it would suggest a distinct role for GFAP, as well as for astrocytes, in glutamatergic 
dysfunction in schizophrenia. 
 
5.4.1 Astrocyte-mediated changes to excitatory transmission via GFAP expression 
occur during states of dehydration and stress. 
The circumstances surrounding lactation are distinct, including the brain regions 
and signaling molecules involved, and the resulting behavior.  Examining other 
circumstances in which astrocytes influence excitatory transmission by retracting 
processes from the synapse may uncover a novel facet of GFAP involvement in 
glutamatergic dysfunction in schizophrenia.  During lactation, the retraction of astrocytic 
processes and decreases in GFAP immunoreactivity has been shown to occur in a matter 
of hours.  These events have also been observed in rats during states of dehydration and 
under physical and psycho-social stressors (Hatton, 1997).  In the SON of dehydrated 
rats, in addition to process retraction which has been confirmed by reports of decreased 
astrocyte process surface area, astrocytes have been shown to undergo a 90o change in 
orientation relative to the pial surface (Bobak and Salm, 1996).  This reversible 
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reorganization of the astrocyte cytoskeleton and decrease in GFAP immunoreactivity, 
interestingly, is accompanied by an increase in GFAP mRNA (Hawrylak et al., 1998; 
Lally et al., 2005).  The absence of GFAP has already been shown to result in an inability 
to extend processes toward neurons in cultured astrocytes (Weinstein et al., 1991).  These 
examples in the lactating and dehydrated rat confirm this phenomenon in vivo.  In culture, 
re-introducing GFAP restores the ability to extend processes (Chen and Liem, 1994).  
Likewise, a reversible structural relationship where GFAP expression leads to 
reestablishment of synaptic coverage by astrocytes exists in the rat brain (Hawrylak et al., 
1998). 
In addition, stress induced activation of the hypothalamic-pituitary-adrenal (HPA) 
system is hypothesized to play a role in astrocyte-mediated synaptic plasticity.  During 
restraint stress, rats exhibit structural reorganizations in the SON similar to those under 
conditions of lactation and dehydration, and adrenalectomy lessens astrocyte process 
retraction (Miyata et al., 1994; Hatton, 1997).  Interestingly, it was shown long ago that 
behavior can induce astrocyte-mediated synaptic plasticity as well.  Studies show that 
non-lactating (virgin) rats that engage in maternal behavior show qualitatively similar 
changes in the SON (Salm et al., 1988).   
Together, these data demonstrate that in addition to the case of lactation, 
astrocytes regulate excitatory transmission by altering the expression of GFAP in a 
variety of situations including dehydration, stress, and behavioral manipulations.  
 
5.4.2 Astrocyte-mediated changes to excitatory transmission via GFAP expression in 
the SON involves glutamatergic molecules implicated in schizophrenia. 
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The SON is not an area associated with schizophrenia.  It is, however, an optimal 
target site for the study of the effects and mechanisms of astrocytic modulation of 
excitatory transmission.  Because the SON expresses molecules that are implicated in 
glutamatergic dysfunction in other brain regions in schizophrenia, it could also be a 
relevant model of glutamatergic dysfunction in schizophrenia.  Studies show that the 
SON contains neurons and astrocytes that express the same molecules that synthesize, 
transport, cycle, and bind glutamate in brain regions implicated in glutamatergic 
dysfunction in schizophrenia.  These molecules include glutamate receptors, such as 
mGluR, NMDA and AMPA receptors, and the glutamate transporters VGLUTs and 
EAATs (Ponzio et al., 2006).  In addition, the SON similarly contains a large population 
of astrocytes expressing enzymes such as glutamine synthetase and serine racemase 
(Panatier et al., 2006).    
Furthermore, brain regions in the present body of work exhibit environmental 
similarities to those found in the SON.  For example, like the SON, the hippocampus is 
an area that is densely covered by astrocytic processes that also undergoes synaptic 
plasticity mediated by glutamate function, which suggests that astrocyte-mediated 
excitatory transmission in the SON may be a relevant model of glutamatergic dysfunction 
in brain regions such as the hippocampus. 
 
5.4.3 Astrocyte-mediated changes to excitatory transmission via GFAP expression can 
account for abnormal brain function in schizophrenia.   
Abnormal structure and function have been shown in various regions in the brain 
in schizophrenia.  These include volumetric changes, abnormal activation, and aberrant 
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functional connectivity (Assaf et al., 2006; Garrity et al., 2007), all of which can be 
attributed to altered GFAP expression. 
Loss of brain volume in schizophrenia likely has an astrocytic component.  One 
study found an 81% increase in GFAP(+) cell bodies, but a 32% reduction in the area 
occupied by these cells, a phenomenon that has been interpreted as evidence of decreased 
processes branching in this illness (Rajkowska et al., 1998; Rajkowska et al., 2002).  
Likewise, abnormal activation in schizophrenia can be linked to astrocytes through GFAP 
expression changes.  As has been described previously, decreased GFAP expression 
leading to the retraction of astrocytic processes from synapses can result in region-
specific increases in excitability and can alter the potentiation threshold of synapses.  In 
theory then, astrocytes can respond to regions of abnormally high or low activation by 
altering the degree of process extension within the synapse.  Conceivably, my findings of 
altered GFAP expression in schizophrenia may represent a compensatory retraction of 
processes in response to glutamatergic hypofunction.  Alternatively, decreased GFAP 
expression may be a marker for brain regions that are unable to regulate excitatory 
transmission in schizophrenia such as the STG and ACC.  
In the ACC, I have detected increased GFAP mRNA and decreased protein.  
These discordant expression changes are the same as those reported in the SON of 
dehydrated rats (Hawrylak et al., 1998; Lally et al., 2005).  So, ACC glutamatergic 
dysfunction in schizophrenia may be associated with changes in the expression of GFAP 
made to compensate for glutamatergic hypofunction.   Furthermore, I detected decreased 
GFAP expression in the STG, which is consistent with studies showing abnormal 
deactivation during working memory tasks in patients with schizophrenia (Walter et al., 
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2007).  This suggests that in some brain regions altered GFAP expression may underlie 
glutamatergic dysfunction in schizophrenia.   
Whether causal or compensatory, these results suggest that astrocyte process 
retraction mediating changes to excitatory transmission and synaptic plasticity may also 
occur under illness-related conditions.  Furthermore, if GFAP expression changes are 
indicative of the type of astrocyte-mediated plasticity observed in the SON, it would 
implicate astrocytes in dysfunctional connectivity seen across multiple brain regions in 
this illness.   
 
5.5 Future Directions 
In situ hybridization and Western blot analysis are useful means of analyzing 
transcript and protein expression changes within a brain region; however, neither 
technique is designed to determine whether discrete populations of astrocytes are 
exhibiting expression changes.  Astrocytes are a heterogeneous cell type displaying 
different phenotypes and physiologies, thus, it would be advantageous to identify the 
specific population(s) of astrocytes involved in the pathophysiology of schizophrenia.  
For example, several studies identify serine racemase-expressing astrocytes as being 
GFAP(+) and acknowledge the existence of astrocytes which co-express GFAP, glutamine 
synthetase, and serine racemase (Schell et al., 1995; Wolosker et al., 1999; Xia et al., 
2004; Williams et al., 2006).  However, the localization of serine racemase has also been 
attributed to GFAP(-) cells (Schell et al., 1995).  The techniques used were not designed to 
identify whether serine racemase expression abnormalities are found in the same 
population of astrocytes that were found to exhibit altered expression of GFAP and 
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glutamine synthetase, but cell level expression studies, though they have proved 
technically challenging when studying these astrocytic molecules in the past, would help 
clarify the source of expression changes.   
This dissertation work was composed of human postmortem studies that identified 
molecular abnormalities specific to astrocytes in schizophrenia.  I found that three key 
astrocytic molecules involved in glutamatergic dysfunction in schizophrenia are 
abnormally expressed, therefore, further studies examining transcript and protein 
expression could identify other intracellular abnormalities specific to astrocytes and 
further clarify the role of these cells in brain dysfunction.  For example, because of its 
role in modulating the phosphorylation of GFAP and multiple reports of altered CSF and 
serum levels in patients with schizophrenia, S100β is an interesting molecule for further 
study.  The expression of GFAP has been shown to alter astrocyte process morphology 
and in turn glutamatergic function, but the mechanisms regulating the assembly and 
disassembly of GFAP, such as interactions with the signaling molecule S100β, have not 
yet been studied in schizophrenia.  Techniques such as the co-immunoprecipitation of 
GFAP and S100β could help determine whether abnormal association of these two 
molecules occurs in schizophrenia.  Preliminary studies indicate that “pulling down” one 
molecule from brain homogenate using protein A/G beads and then measuring protein 
expression interactions using Western blot analysis could be successfully employed 
(Figure 5.4).  The IF molecule vimentin has also been shown to affect GFAP expression 
and organization, however, few studies have examined this molecule in schizophrenia.  
Additionally, measuring the expression of phosphorylated isoforms of GFAP could 





Figure 5.4 Western blots of GFAP and S100β co-immunoprecipitation experiments.  
The interactions between GFAP and S100β can be studied using co-immunoprecipitation.   
Preliminary studies demonstrate that each molecule can be extracted from human brain 
homogenate using A/G protein beads and detected using Western blot analysis. 
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commercial antibodies available to identify phosphorylated isoforms of GFAP, I failed to 
detect a signal in preliminary studies using Western blot analysis.  Further study is 
needed to determine whether GFAP phosphorylation is maintained in human postmortem 
tissue during the homogenization process.   
 A role for GFAP expression in astrocyte-mediated excitatory transmission 
has been described.   The degree of astrocyte process extension can influence aspects of 
glutamatergic function, such as the synthesis and release of D-serine in proximity of the 
glutamatergic synapse and the reuptake of synaptic glutamate via EAATs.  However, the 
type of plasticity mediated by GFAP that, in the SON, results in altered potentiation and 
increased neuronal excitability has not been described in schizophrenia.  Since NMDA 
receptor hypofunction can account for all categories of symptoms in schizophrenia and 
studies have concluded that NMDA receptor antagonism, when occurring long term, may 
be a relevant pharmacological model of this illness (Newell et al., 2007), it would be 
interesting to determine whether PCP administration in rats would alter GFAP expression 
and process retraction in the SON and other brain regions.   
The plastic changes seen in the SON during lactation, dehydration, and stress 
involve the neuroendocrine molecules oxytocin and vasopressin.  There is some evidence 
that increased levels of oxytocin and vasopressin in CSF and plasma occur in both 
medicated and non-medicated patients with schizophrenia (Legros et al., 1992).  The 
relationship between these molecules and schizophrenia are unclear, but studies suggest 
that altered levels of oxytocin and vasopressin in peripheral fluids may be secondary to 
dopaminergic abnormalities (Meltzer et al., 2001).  Tying astrocyte-mediated dysfunction 
to other neurotransmitter and endocrine functions may uncover novel avenues of 
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pharmacological treatment in this illness.   
The study of serine racemase is relatively new and my finding of increased serine 
racemase expression in the hippocampus was the first published in the schizophrenia 
literature.  Examining serine racemase expression in multiple brain regions and in 
specific populations of astrocytes is an obvious next step.  Additionally, further 
explorations of serine racemase using an assay to determine whether the activity of this 
enzyme is altered in schizophrenia and co-immunoprecipitation experiments to examine 
protein interactions of serine racemase could be performed.  I attempted to measure the 
activity of serine racemase from human postmortem brain homogenates using an assay 
described by Cook et al. that quantifies a breakdown product of D-serine (Cook et al., 
2002) (Figure 5.5).  Although this assay has been successfully used with purified serine 
racemase, measuring activity levels in brain homogenate proved technically challenging.   
Recent literature demonstrates astrocytic expression of AMPA receptors and 
interacting proteins which facilitate receptor trafficking and expression (Kim et al., 2005; 
Fujii et al., 2006).  I performed some preliminary experiments in which I 
immunoprecipitated serine racemase from human brain homogenate and probed for 
proteins that associated with it.  Consistent with other reports, I detected GRIP1 and 
PICK1.  However, I also detected neurofilament light chain (NFL), a neuronal marker 
being used as a negative control.  One interpretation for the association of NFL with 
serine racemase is that while these molecules do not exhibit intracellular interactions, 
they may do so during the homogenation process.  In light of new information 
demonstrating serine racemase expression in neurons (Kartvelishvily et al., 2006; 





Figure 5.5 Enzymatic assay for serine racemase activity.  In the presence of DAAO, 
D-serine is converted to α-keto acid, ammonia, and H2O2.  Hydrogen peroxide can be 
measured using a horseradish peroxidase-based assay and the peroxidase substrate o-
phenylenediamine, the oxidation of which produces a quantifiable yellow color 
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serine racemase.  However, this seems unlikely as serine racemase expression in neurons 
has only been shown in measurable quantities in the cerebellum and hindbrain, whereas I 
used cortical tissue in these co-immunoprecipitation experiments.  Additionally, other 
neuronal molecules such as PSD95 were not detected in association with serine racemase 
suggesting that neuronal origin of the serine racemase is unlikely (Figure 5.6). 
In addition to serine racemase, other astrocytic enzymes involved in glutamatergic 
function, such as glutamine synthetase, warrant further study.  The literature describing 
the activity of glutamine synthetase in schizophrenia so far has shown mixed results and 
suggests that multiple isoforms of glutamine synthetase may be involved in the abnormal 
expression and perhaps activity of this enzyme in schizophrenia. 
 
5.6 Conclusions 
Schizophrenia is an illness that emerges as a result of complex interactions 
between genetics and environment.  Developmental abnormalities are hypothesized to 
underlie illness-related brain abnormalities.  Historically, neuronal dysfunction has been 
the main hallmark of schizophrenia; however, an increasing awareness of the diverse role 
played by astrocytes also implicates these cells.  Specifically, astrocytes play a prominent 
role in glutamate function.  Astrocytes mediate synaptic transmission at the glutamate 
synapse in three fundamental ways: 1) the expression of serine racemase determines D- 
serine occupancy of the co-agonist site on NMDA receptors, which helps ensure receptor 
activation during input stimulation; 2) EAAT-mediated uptake of synaptic glutamate and 
recycling by glutamine synthetase provides metabolic substrate and transmitter molecules 






Figure 5.6 Serine racemase co-immunoprecipitation experiment.  I successfully 
immunoprecipitated and detected serine racemase using protein A/G beads and Western 
blot analysis from (a) rat liver and brain, and from monkey brain tissue.  I performed the 
same technique with (b) human brain homogenate and probed for proteins that co-
immunoprecipitated.  I detected the AMPA receptor interacting proteins GRIP1 and 
PICK1, as well as a neuronal molecule, NFL.  I did not detect the neuronal molecule 







activation of distant synapses and excitotoxicity; and 3) GFAP expression and the 
retraction of processes from typically ensheathed synapses can result in a spatially and 
temporally coordinated activation of synapses.  
 Our findings suggest that astrocytes do contribute to the pathophysiology of 
schizophrenia, and that astrocytic molecules involved in cytoskeletal integrity and 
glutamatergic function are compromised in this illness.  A complex illness such as 
schizophrenia requires a reappraisal of the existing neuro-centric model to include an 
astrocytic hypothesis of dysfunction, which could lead to a more complete understanding 
of schizophrenia, and perhaps provide a novel target for treatment strategies in this 
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